



PCT/EP 03/03661



Rec'd PCT/PTO 22 SEP 2004

RECD 02 MAY 2003	
The Patent Office	
WIPO	Concept House
Cardiff Road	
Newport	
South Wales	
NP10 8QQ	

[Handwritten signature]

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Signed *Andrew George*

Dated 17 March 2003

BEST AVAILABLE COPY

-7 FEB 2003

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

10FEB03 E783461-1 D02029
P01/7700 0.00-0302881.8The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

DES/HG/PB60056

2. Patent application number

(The Patent Office will fill in his part)

07 FEB 2003

0302881.8

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Glaxo Group Limited
Glaxo Wellcome House, Berkeley Avenue,
Greenford, Middlesex UB6 0NN, Great Britain

Patents ADP number (if you know it) 00473587003

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

Compounds

5. Name of your agent (if you have one)

Corporate Intellectual Property

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

GlaxoSmithKline
Corporate Intellectual Property (CN9 25.1)
980 Great West Road
BRENTFORD
Middlesex TW8 9GS

Patents ADP number (if you know it)

07966988003

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number

Country Priority application number Date of filing
(if you know it) (day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer yes if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is named as an applicant, or
- c) any named applicant is a corporate body

See note (d)

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form
 Description 61
 Claim(s) 1
 Abstract *JML*
 Drawings

10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents
(please specify)

11.

We request the grant of a patent on the basis of this application

Signature *K Rutter* Date 7-Feb-03
K Rutter

12. Name and daytime telephone number of person to contact in the United Kingdom

K Rutter 01279 644396

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- For details of the fee and ways to pay please contact the Patent Office.

COMPOUNDS

This invention relates to cyclopentene compounds, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine, in particular their use in 5 the treatment of prostaglandin mediated diseases.

The EP₁ receptor is a 7-transmembrane receptor and its natural ligand is the prostaglandin PGE₂. PGE₂ also has affinity for the other EP receptors (types EP₂, EP₃ and EP₄). The EP₁ receptor is associated with smooth muscle contraction, pain (in particular inflammatory, neuropathic and visceral), inflammation, allergic activities, renal regulation and gastric or enteric mucus secretion.

10 We have now found a novel group of compounds which bind with high affinity to the EP₁ receptor.


A number of review articles describe the characterization and therapeutic relevance of the prostanoid receptors as well as the most commonly used selective agonists and antagonists: *Eicosanoids; From Biotechnology to Therapeutic Applications*, Folco, Samuelsson, Maclouf, and Velo eds, Plenum Press, New York, 1996, chap. 14, 137-154 and *Journal of Lipid Mediators and Cell*

15 *Signalling*, 1996, 14, 83-87 and *Prostanoid Receptors, Structure, Properties and Function*, S Narumiya et al, *Physiological Reviews* 1999, 79(4), 1193-126. An article from *The British Journal of Pharmacology* (1994, 112, 735- 740) suggests that Prostaglandin E₂ (PGE₂) exerts allodynia through the EP₁ receptor subtype and hyperalgesia through EP₂ and EP₃ receptors in the ~~rat~~ spinal cord. Furthermore an article from *The Journal of Clinical Investigation* (2001, 107 (3), 335) shows that in 20 the EP₁ knock-out mouse pain-sensitivity responses are reduced by approximat~~ly~~ 50%. Two papers from *Anesthesia and Analgesia* have shown that (2001, 93, 1012-7) an EP₁ receptor antagonist (ONO- 8711) reduces hyperalgesia and allodynia in a rat model of chronic constriction injury, and that (2001, 92, 233-238) the same antagonist inhibits mechanical hyperalgesia in a rodent model of post-operative pain. Thus, selective prostaglandin ligands, agonists or antagonists, depending on which prostaglandin 25 E receptor subtype is being considered, have anti-inflammatory, antipyretic and analgesic properties similar to a conventional non-steroidal anti-inflammatory drug, and in addition, inhibit hormone-induced uterine contractions and have anti-cancer effects. These compounds have a diminished ability to induce some of the mechanism-based side effects of NSAIDs which are indiscriminate cyclooxygenase inhibitors. In particular, the compounds have a reduced potential for gastrointestinal 30 toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects. Moreover, by sparing potentially beneficial prostaglandin pathways, these agents may have enhanced efficacy over NSAIDS and/or COX-2 inhibitors.

In The American Physiological Society (1994, 267, R289-R-294), studies suggest that PGE₂- 35 induced hyperthermia in the rat is mediated predominantly through the EP₁ receptor.

WO 96/06822 (March 7, 1996), WO 96/11902 (April 25, 1996), EP 752421-A1 (January 08, 1997) and WO 01/19814 (22 March 2001) disclose compounds as being useful in the treatment of prostaglandin mediated diseases.

Accordingly the present invention provides compounds of formula (I):



(I)

5 wherein:

A represents an optionally substituted phenyl, or an optionally substituted 5- or 6- membered heterocyclyl group;

R¹ represents CO₂R⁴, CONR⁵R⁶, CH₂CO₂R⁴, optionally substituted C₁₋₆alkyl, optionally substituted C₁₋₆alkenyl, SO₂C₁₋₆alkyl, SO₂NR⁵R⁶, NR⁵CONR⁵R⁶, tetrazolyl or CONR⁵R⁶;

10 R² independently represents halo, optionally substituted C₁₋₆alkyl, CN, SO₂R⁵, SOR⁵, NO₂, optionally substituted aryl, CONR⁵R⁶ or optionally substituted heteroaryl;

R^x represents optionally substituted C₁₋₆alkyl or optionally substituted -CH₂-phenyl;

R⁴ represents hydrogen or an optionally substituted C₁₋₆alkyl;

R⁵ represents hydrogen or an optionally substituted C₁₋₆alkyl;

15 R⁶ represents hydrogen or an optionally substituted C₁₋₆alkyl, optionally substituted SO₂aryl, optionally substituted SO₂heterocyclyl group, CN, optionally substituted CH₂aryl or COR⁷;

R⁷ represents hydrogen or an optionally substituted aryl;

R⁸ and R⁹ independently represent hydrogen or C₁₋₆alkyl;

n is an integer from 0 to 2;

20 wherein R¹ is attached to the group A in the 3 or 4 position relative to the bond attaching A to the cyclopentene ring;

or pharmaceutically acceptable derivatives thereof.

Preferably R¹ is attached to the group A in the 3 position relative to the bond attaching A to the cyclopentene ring.

25 Preferably A is selected from phenyl, pyridyl, pyridazinyl, pyrazinyl or pyrimidinyl, all of which may be optionally substituted. In an other aspect, A is selected from an optionally substituted phenyl, pyridyl, pyridazinyl, pyrazinyl or pyrimidinyl; more preferably A is pyridyl or an optionally substituted phenyl; most preferably A is optionally substituted phenyl. In an alternative aspect A is pyridyl.

30 In an alternative aspect, A is optionally substituted phenyl or a 5- or 6-membered heterocyclyl group.

Optional substituents for A when a phenyl group include up to four substituents independently selected from halogen, NR^5R^6 , $NR^5COC_{1-6}alkyl$, $NR^5SO_2C_{1-6}alkyl$, OR^5 , $C_{1-6}alkyl$ and $NR^{10}R^{11}$ wherein R^{10} and R^{11} together with the nitrogen atom to which they are attached form a morpholine ring, a 5- or 6-membered lactam ring or a 5- or 6-membered cyclic sulphonamide, wherein

5 R^5 and R^6 are as defined above.

In an alternative aspect optional substituents for A when a phenyl group include up to four substituents independently selected from $C_{1-6}alkyl$, $C_{1-6}alkoxy$ and halogen. Preferably A when a phenyl group is optionally substituted by up to 2 substituents.

Optional substituents for A when a 5- or 6-membered heterocyclyl group include NH_2 . When A 10 is pyridyl it may be substituted on the ring nitrogen by an oxygen to give a pyridine N-oxide.

In an alternative aspect R^1 represents CO_2R^4 , $CONR^5R^6$, $CH_2CO_2R^4$, optionally substituted $C_{1-6}alkyl$, optionally substituted $C_{1-6}alkenyl$, $SO_2C_{1-6}alkyl$, $SO_2NR^5R^6$, $NR^5CONR^5R^6$, tetrazolyl or $COSO_2NR^5R^6$.

In another aspect R^2 independently represents halo, optionally substituted $C_{1-6}alkyl$, CN , 15 SO_2R^5 , NO_2 , optionally substituted aryl, $CONR^5R^6$ or optionally substituted heteroaryl.

In an alternative aspect R^6 represents hydrogen or an optionally substituted $C_{1-6}alkyl$, optionally substituted SO_2 aryl, optionally substituted SO_2 heterocyclyl group, CN , or COR^7 .

Preferably R^1 represents CO_2R^4 .


Preferably R^2 represents halogen, optionally substituted $C_{1-6}alkyl$, for example CF_3 , CN , 20 $SC_{1-6}alkyl$ or $SO_2C_{1-6}alkyl$. Alternatively R^2 represents halogen, optionally substituted $C_{1-6}alkyl$, for example CF_3 , CN or $SO_2C_{1-6}alkyl$

Preferably R^8 represents methyl or H.

Preferably R^9 represents H.

When R^x represents an optionally substituted $C_{1-8}alkyl$, the alkyl group is preferably CH_2C_5 . 25 $cycloalkyl$.

Preferred compounds of formula (I) are compounds of formula (II):



(II)

wherein:

R¹ is CO₂R⁴;

R² is halogen, optionally substituted C₁₋₆alkyl, for example CF₃, CN, SC₁₋₆alkyl or SO₂C₁₋₆alkyl;

R³ independently represents halo or an optionally substituted OC₁₋₆alkyl, or C₁₋₆alkyl;

m is an integer from 0 to 2;

5 n is an integer from 0 to 2;

W, X, Y and Z represents CH or N wherein at least one of W, X, Y or Z is CH;

or pharmaceutically acceptable derivatives thereof.

In an alternative aspect R² is halogen, optionally substituted C₁₋₆alkyl, for example CF₃, CN, or SO₂C₁₋₆alkyl;

10 Preferably R³ represents halo or optionally substituted OC₁₋₆alkyl more preferably halo or OMe.

Preferred compounds are selected from:

3-{2-[5-chloro-2-(benzyloxy)phenyl]cyclopent-1-enyl}-benzoic acid;

3-{2-[(2-benzyloxy)phenyl]cyclopent-1-enyl}-benzoic acid;

15 3-{2-[5-bromo-2-(benzyloxy)phenyl]cyclopent-1-enyl}-benzoic acid;

3-{2-[5-bromo-2-(4-chlorobenzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;

3-{2-[5-bromo-2-(4-fluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;

3-{2-[5-bromo-2-(3,4-dichlorobenzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;

3-{2-[5-bromo-2-(2,4-difluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;

20 3-{2-[5-bromo-2-(4-chloro-2-fluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;

3-{2-[5-bromo-2-(4-methoxybenzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;

5-{2-[5-chloro-2-(4-chlorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

5-{2-[5-chloro-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

5-{2-[5-chloro-2-(4-fluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

25 5-{2-[5-chloro-2-(3,4-dichlorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

5-{2-[5-chloro-2-(2,4-difluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

5-{2-[5-chloro-2-(4-chloro-2-fluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

5-{2-[5-chloro-2-(4-methoxybenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

5-{2-[5-bromo-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

30 5-{2-[5-bromo-2-(4-chlorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

5-{2-[5-bromo-2-(4-fluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

5-{2-[5-bromo-2-(2,4-difluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

5-{2-[5-bromo-2-(4-chloro-2-fluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

5-{2-[5-bromo-2-(4-methoxybenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

35 5-{2-[5-bromo-2-(cyclohexylmethoxy)phenyl]cyclopent-1-enyl} nicotinic acid;

5-{2-[5-trifluoromethyl-2-(4-chlorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

5-{2-[5-trifluoromethyl-2-(4-fluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

5-{2-[5-trifluoromethyl-2-(2,4-difluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid;

5-{2-[5-trifluoromethyl-2-(4-chloro-2-fluorobenzyl)oxy]-phenyl]-cyclopent-1-enyl}-nicotinic acid;
5-{2-[5-trifluoromethyl-2-(cyclohexylmethoxy)phenyl]-cyclopent-1-enyl}nicotinic acid;
6-{2-[5-chloro-2-(2,4-difluorobenzyl)oxy]-phenyl]-cyclopent-1-enyl}-pyridine-2-carboxylic acid;
6-{2-[5-chloro-2-(4-chloro-2-fluorobenzyl)oxy]-phenyl]-cyclopent-1-enyl}-pyridine-2-carboxylic
5 acid;
6-{2-[5-chloro-2-(4-chlorobenzyl)oxy]-phenyl]-cyclopent-1-enyl}-pyridine 2-carboxylic acid;
6-{2-[5-chloro-2-(4-fluorobenzyl)oxy]-phenyl]-cyclopent-1-enyl}-pyridine 2-carboxylic acid;
3-{2-[5-methylsulfanyl-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;
3-{2-[5-methanesulfonyl-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;
10 3-{2-[5-methylsulfanyl-2-(4-fluoro-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;
3-{2-[5-methanesulfonyl-2-(4-fluoro-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;
3-{2-[5-methylsulfanyl-2-(2,4-difluoro-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;
3-{2-[5-methanesulfonyl-2-(2,4-difluoro-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;
3-{2-[2-(2,4-difluoro-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;
15 3-{2-[2-(4-chloro-2-fluoro-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;
3-{2-[2-(4-methoxy-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;
3-{2-[5-cyano-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid; and
3-{2-[5-cyano-2-(2,4-difluoro-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid;
and pharmaceutically acceptable derivatives thereof.

20 Preferably compounds are selective for EP₁ over EP₃. More preferably the compounds are
100 fold selective, more preferably 1000 fold selective for EP₁ over EP₃.

The invention is described using the following definitions unless otherwise indicated.

25 The term "pharmaceutically acceptable derivative" means any pharmaceutically acceptable
salt, ester, salt of such ester or solvate of the compounds of formula (I), or any other compound
which upon administration to the recipient is capable of providing (directly or indirectly) a
compound of formula (I) or an active metabolite or residue thereof.

30 It will be appreciated by those skilled in the art that the compounds of formula (I) may be
modified to provide pharmaceutically acceptable derivatives thereof at any of the functional groups
in the compounds, and that the compounds of formula (I) may be derivatised at more than one
position.

35 It will be appreciated that, for pharmaceutical use, the salts referred to above will be
physiologically acceptable salts, but other salts may find use, for example in the preparation of
compounds of formula (I) and the physiological acceptable salts thereof. Pharmaceutically
acceptable salts include those described by Berge, Bighley and Monkhouse, J. Pharm. Sci., 1977,
66, 1-19. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically
acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic
bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganese
salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium,

calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol,

5 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropyl amine, tromethamine, and the like. When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic 10 and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acid.

15 Preferred examples of pharmaceutically acceptable salts include those formed from maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, propionic, tartaric, salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, cyclohexylsulfamic, phosphoric and nitric acids.

20 The terms "halogen or halo" are used to represent fluorine, chlorine, bromine or iodine.

The term "alkyl" as a group or part of a group means a straight, branched or cyclic chain alkyl group or combinations thereof, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, pentyl, hexyl, 1,1-dimethylethyl, cyclopentyl or cyclohexyl or combinations thereof.

25 The term "alkoxy" as a group or as part of a group means a straight, branched or cyclic chain alkyl group having an oxygen atom attached to the chain, for example a methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy group, pentoxy, hexyloxy group, cyclopentoxy or cyclohexyloxy group.

The term "haloalkyl" means an alkyl group, including straight, branched or cyclic structures, of the indicated number of carbon atoms in which one or more hydrogen atoms have been replaced by 30 halogen atoms, with up to complete substitution of all hydrogen atoms with halo groups. C_{1-6} haloalkyl, for example, includes C_{1-6} fluoroalkyl, e.g. CF_3 , CF_2CF_3 and the like.

The term "haloalkoxy" means an alkoxy group, including straight, branched or cyclic structures, of the indicated number of carbon atoms in which one or more hydrogen atoms have been replaced by halogen atoms, with up to complete substitution of all hydrogen atoms with halo groups.

35 C_{1-6} haloalkoxy, for example, includes C_{1-6} fluoroalkoxy e.g. OCF_3 , OCF_2CF_3 and the like.

The term "alkenyl" means linear or branched structures and combinations thereof, of the indicated number of carbon atoms, having at least one carbon-to-carbon double bond, wherein hydrogen

may be replaced by an additional carbon to carbon double bond. C_{2-6} alkenyl, for example, includes ethenyl, propenyl, 1-methylethenyl, butenyl and the like.

The term "heterocyclyl" as a group or as part of a group means an aromatic or non-aromatic five or six membered ring which contains from 1 to 4 heteroatoms selected from nitrogen, oxygen or sulfur and unsubstituted or substituted by, for example, up to three substituents. Examples of 5-membered heterocyclyl groups include furyl, dioxalanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, triazinyl, isothiazolyl, isoxazolyl, thiophenyl, pyrazolyl or tetrazolyl. Examples of 6-membered heterocyclyl groups are pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl or tetrazinyl.

The term "aryl" as a group or part of a group means a 5- or 6- membered aromatic ring, for example phenyl, or a 7 to 12 membered bicyclic ring system where at least one of the rings is aromatic, for example naphthyl. An aryl group may be optionally substituted by one or more substituents, for example up to 4, 3 or 2 substituents. Preferably the aromatic group is phenyl.


The term "heteroaryl" as a group or as part of a group means a monocyclic five or six membered aromatic ring, or a fused bicyclic aromatic ring system comprising two of such monocyclic five or six membered aromatic rings. These heteroaryl rings contain one or more heteroatoms selected from nitrogen, oxygen or sulfur, where N-oxides, sulfur oxides and sulfur oxides are permissible heteroatom substitutions. A heteroaryl group may be optionally substituted by one or more substituents, for example up to 3 or up to 2 substituents. Examples of "heteroaryl" used herein include furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, indolyl, and indazolyl.

When nitrogen is present in a heteroaryl or heterocyclyl group the nitrogen atom will, where appropriate, be substituted by hydrogen or C_{1-8} alkyl, preferably hydrogen or C_{1-6} alkyl, more preferably hydrogen.

Optional substituents for alkyl or alkenyl groups are OH, CO_2R^4 , NR^4R^5 , (O), OC_{1-6} alkyl or halo, wherein R^4 and R^5 are as herein before defined. An alkyl or alkenyl group may be substituted by one or more optional substituents, for example up to 5, 4, 3, or 2 optional substituents.

Unless otherwise defined optional substituents for aryl, heteroaryl or heterocyclyl moieties as a group or part of a group are selected from optionally substituted C_{1-6} alkyl, optionally substituted C_{1-6} alkoxy and halogen. Alternative optional substituents include C_{1-6} alkyl, C_{1-6} alkoxy and halogen.

Compounds of formula (I) can be prepared as set forth in the following scheme.



5 wherein L^1 , L^2 , are leaving groups for example halo, or triflate; L^3 and L^4 is an activating group for example selected from stannanes including trialkystannane, and boranes including boronic acid and boronate; P is a protecting group for example methyl or ethyl esters; and A , R^8 , R^9 and R^x are as defined for compounds of formula (I). L^1 can be converted to L^1' , wherein L^1' is an activating group for example a stannane or borane, and in this situation L^4 can be halo or triflate.

10 It is to be understood that the present invention encompasses all isomers of formula (I) and their pharmaceutically acceptable derivatives, including all geometric, tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures). Where additional chiral centres are present in compounds of formula (I), the present invention includes within its scope all possible diastereoisomers, including mixtures thereof. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

15 The compounds of the invention bind to the EP_1 receptor and are therefore useful in treating EP_1 receptor mediated diseases.

20 In view of their ability to bind to the EP_1 receptor, the compounds of the invention may be useful in the treatment of the disorders that follow. Thus, the compounds of formula (I) may be useful as analgesics. For example they may be useful in the treatment of chronic articular pain (e.g. rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis) including the property of disease modification and joint structure preservation; musculoskeletal pain; lower back and neck pain; sprains and strains; neuropathic pain; sympathetically maintained pain; myositis; pain associated with cancer and fibromyalgia; pain associated with migraine; pain associated with influenza or other viral infections, such as the common cold; rheumatic fever; pain associated with functional bowel disorders such as non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome; pain associated with myocardial ischemia; post operative pain; headache;

toothache; and dysmenorrhea. The compounds of the invention may also be useful in the treatment of visceral pain.

The compounds of the invention may be particularly useful in the treatment of neuropathic pain. Neuropathic pain syndromes can develop following neuronal injury and the resulting pain may persist for months or years, even after the original injury has healed. Neuronal injury may occur in the peripheral nerves, dorsal roots, spinal cord or certain regions in the brain. Neuropathic pain syndromes are traditionally classified according to the disease or event that precipitated them. Neuropathic pain syndromes include: diabetic neuropathy; sciatica; non-specific lower back pain; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; post-herpetic neuralgia; trigeminal neuralgia; and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions. These conditions are difficult to treat and although several drugs are known to have limited efficacy, complete pain control is rarely achieved. The symptoms of neuropathic pain are incredibly heterogeneous and are often described as spontaneous shooting and lancinating pain, or ongoing, burning pain. In addition, there is pain associated with normally non-painful sensations such as "pins and needles" (paraesthesia and dysesthesia), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static or thermal allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hyporeactivity).

The compounds of formula (I) may also be useful in the treatment of fever.

The compounds of formula (I) may also be useful in the treatment of inflammation, for example in the treatment of skin conditions (e.g. sunburn, burns, eczema, dermatitis, psoriasis); ophthalmic diseases such as glaucoma, retinitis, retinopathies, uveitis and of acute injury to the eye tissue (e.g. conjunctivitis); lung disorders (e.g. asthma, bronchitis, emphysema, allergic rhinitis, respiratory distress syndrome, pigeon fancier's disease, farmer's lung, chronic obstructive pulmonary disease, (COPD); gastrointestinal tract disorders (e.g. aphthous ulcer, Crohn's disease, atopic gastritis, gastritis varialoforme, ulcerative colitis, coeliac disease, regional ileitis, irritable bowel syndrome, inflammatory bowel disease, gastrointestinal reflux disease); organ transplantation; other conditions with an inflammatory component such as vascular disease, migraine, periarthritis nodosa, thyroiditis, aplastic anaemia, Hodgkin's disease, sclerodema, myasthenia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, Bechet's syndrome, polymyositis, gingivitis, myocardial ischemia, pyrexia, systemic lupus erythematosus, tendinitis, bursitis, and Sjogren's syndrome.

The compounds of formula (I) are also useful in the treatment of immunological diseases such as autoimmune diseases, immunological deficiency diseases or organ transplantation. The compounds of formula (I) are also effective in increasing the latency of HIV infection.

The compounds of formula (I) are also useful in the treatment of diseases of abnormal platelet function (e.g. occlusive vascular diseases).

The compounds of formula (I) are also useful for the preparation of a drug with diuretic action.

The compounds of formula (I) are also useful in the treatment of impotence or erectile dysfunction.

5 The compounds of formula (I) are also useful in the treatment of bone disease characterised by abnormal bone metabolism or resorption such as osteoporosis (especially postmenopausal osteoporosis), hyper-calcemia, hyperparathyroidism, Paget's bone diseases, osteolysis, hypercalcemia of malignancy with or without bone metastases, rheumatoid arthritis, periodontitis, osteoarthritis, ostealgia, osteopenia, cancer cachexia, calculosis, lithiasis (especially urolithiasis),
10 solid carcinoma, gout and ankylosing spondylitis, tendinitis and bursitis.

The compounds of formula (I) are also useful for attenuating the hemodynamic side effects of non-steroidal anti-inflammatory drugs (NSAID's) and cyclooxygenase-2 (COX-2) inhibitors.

15 The compounds of formula (I) are also useful in the treatment of cardiovascular diseases such as hypertension or myocardial ischemia; functional or organic venous insufficiency; varicose therapy; haemorrhoids; and shock states associated with a marked drop in arterial pressure (e.g. septic shock).

20 The compounds of formula (I) are also useful in the treatment of neurodegenerative diseases and neurodegeneration such as dementia, particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntingdon's chorea, Parkinson's disease and Creutzfeldt-Jakob disease, ALS, motor neuron disease); vascular dementia (including multi-infarct dementia); as well as dementia associated with intracranial space occupying lesions; trauma; infections and related conditions (including HIV infection); metabolism; toxins; anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment.

25 The compounds of formula (I) are also useful in the treatment of neuroprotection and in the treatment of neurodegeneration following stroke, cardiac arrest, pulmonary bypass, traumatic brain injury, spinal cord injury or the like.

The compounds of formula (I) are also useful in the treatment of tinnitus.

30 The compounds of formula (I) are also useful in preventing or reducing dependence on, or preventing or reducing tolerance or reverse tolerance to, a dependence - inducing agent. Examples of dependence inducing agents include opioids (e.g. morphine), CNS depressants (e.g. ethanol), psychostimulants (e.g. cocaine) and nicotine.

35 The compounds of formula (I) are also useful in the treatment of complications of Type 1 diabetes (e.g. diabetic microangiopathy, diabetic retinopathy, diabetic nephropathy, macular degeneration, glaucoma), nephrotic syndrome, aplastic anaemia, uveitis, Kawasaki disease and sarcoidosis.

The compounds of formula (I) are also useful in the treatment of kidney dysfunction (nephritis, particularly mesangial proliferative glomerulonephritis, nephritic syndrome), liver dysfunction (hepatitis, cirrhosis), gastrointestinal dysfunction (diarrhoea) and colon cancer.

It is to be understood that reference to treatment includes both treatment of established

5 symptoms and prophylactic treatment, unless explicitly stated otherwise.

According to a further aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in human or veterinary medicine.

According to another aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is 10 mediated by the action of PGE₂ at EP₁ receptors.

According to a further aspect of the invention, we provide a method of treating a human or animal subject suffering from a condition which is mediated by the action of PGE₂ at EP₁ receptors which comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

15 According to a further aspect of the invention we provide a method of treating a human or animal subject suffering from a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder, which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

According to another aspect of the invention, we provide the use of a compound of formula 20 (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a therapeutic agent for the treatment of a condition which is mediated by the action of PGE₂ at EP₁ receptors.

According to another aspect of the invention we provide the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a therapeutic agent for the treatment or prevention of a condition such as a pain, inflammatory, immunological, bone, 25 neurodegenerative or renal disorder.

The compounds of formula (I) and their pharmaceutically acceptable derivatives are conveniently administered in the form of pharmaceutical compositions. Such compositions may conveniently be presented for use in conventional manner in admixture with one or more physiologically acceptable carriers or excipients.

30 Thus, in another aspect of the invention, we provide a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof adapted for use in human or veterinary medicine.

The compounds of formula (I) and their pharmaceutically acceptable derivatives may be formulated for administration in any suitable manner. They may, for example, be formulated for 35 topical administration or administration by inhalation or, more preferably, for oral, transdermal or parenteral administration. The pharmaceutical composition may be in a form such that it can effect controlled release of the compounds of formula (I) and their pharmaceutically acceptable derivatives.

For oral administration, the pharmaceutical composition may take the form of, for example, tablets (including sub-lingual tablets), capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.

5 For transdermal administration, the pharmaceutical composition may be given in the form of a transdermal patch, such as a transdermal iontophoretic patch.

For parenteral administration, the pharmaceutical composition may be given as an injection or a continuous infusion (e.g. intravenously, intravascularly or subcutaneously). The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. For 10 administration by injection these may take the form of a unit dose presentation or as a multidose presentation preferably with an added preservative.

Alternatively for parenteral administration the active ingredient may be in powder form for reconstitution with a suitable vehicle.

15 The compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

20 The EP₁ receptor compounds for use in the instant invention may be used in combination with other therapeutic agents, for example COX-2 inhibitors, such as celecoxib, deracoxib, rofecoxib, valdecoxib, parecoxib or COX-189; 5-lipoxygenase inhibitors; NSAID's, such as diclofenac, indomethacin, nabumetone or ibuprofen; leukotriene receptor antagonists; DMARD's such as methotrexate; adenosine A1 receptor agonists; sodium channel blockers, such as

25 lamotrigine; NMDA receptor modulators, such as glycine receptor antagonists; gabapentin and related compounds; tricyclic antidepressants such as amitriptyline; neurone stabilising antiepileptic drugs; mono-aminergic uptake inhibitors such as venlafaxine; opioid analgesics; local anaesthetics; 5HT₁ agonists, such as triptans, for example sumatriptan, naratriptan, zolmitriptan, eletriptan, frovatriptan, almotriptan or rizatriptan; nicotinic acetyl choline (nACh) receptor modulators;

30 glutamate receptor modulators, for example modulators of the NR2B subunit; EP₄ receptor ligands; EP₂ receptor ligands; EP₃ receptor ligands; EP₄ antagonists; EP₂ antagonists and EP₃ antagonists; cannabinoid receptor ligands; bradykinin receptor ligands and vanilloid receptor ligand. When the compounds are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.

35 Additional COX-2 inhibitors are disclosed in US Patent Nos. 5,474,995 US5,633,272; US5,466,823, US6,310,099 and US6,291,523; and in WO 96/25405, WO 97/38986, WO 98/03484, WO 97/14691, WO99/12930, WO00/26216, WO00/52008, WO00/38311, WO01/58881 and WO02/18374.

The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent or agents.

5 The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

10 When a compound of formula (I) or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same disease state the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

15 A proposed daily dosage of compounds of formula (I) or their pharmaceutically acceptable derivatives for the treatment of man is from 0.01 to 30 mg/kg body weight per day and more particularly 0.1 to 10 mg/kg body weight per day, calculated as the free base, which may be administered as a single or divided dose, for example one to four times per day. The dose range for adult human beings is generally from 8 to 2000 mg/day, such as from 20 to 1000 mg/day, preferably 35 to 200 mg/day, calculated as the free base.

20 The precise amount of the compounds of formula (I) administered to a host, particularly a human patient, will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors including the age and sex of the patient, the precise condition being treated and its severity, and the route of administration.

25 No unacceptable toxicological effects are expected with compounds of the invention when administered in accordance with the invention.

30 All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The following non-limiting Examples illustrate the preparation of pharmacologically active compounds of the invention.

35

Mass Directed Auto-purification systems

Hardware

Waters 600 gradient pump

35 Waters 2700 sample manager

Waters Reagent Manager

Micromass ZMD mass spectrometer

Gilson 202 - fraction collector

Gilson Aspec - waste collector

Software

Micromass Masslynx version 3.5

5

Column

The column used is typically a Supelco ABZ+ column whose dimensions are 10mm internal diameter by 100mm in length. The stationary phase particle size is 5 μ m.

10

Solvents

A. Aqueous solvent = Water + 0.1% Formic Acid

B. Organic solvent = MeCN: Water 95:5 +0.05% Formic Acid

Make up solvent = MeOH: Water 80:20 +50mMol Ammonium Acetate

Needle rinse solvent = MeOH: Water: DMSO (N,N-dimethyl sulfoxide) 80:10:10

15

Methods

There are five methods used depending on the analytical retention time of the compound of interest.

They all have a 15-minute runtime, which comprises of a 10-minute gradient followed by a 5-minute column flush and re-equilibration step.

20

MDP 1.5-2.2 = 0-30% B

MDP 2.0-2.8 = 5-30% B

MDP 2.5-3.0 = 15-55% B

MDP 2.8-4.0 = 30-80% B

25

MDP 3.8-5.5 = 50-90% B

Flow rate

All of the above methods have a flow rate of 20ml/min.

30

EXPERIMENTAL

Compound I: 4-Chloro-2-iodophenol

(Tetrahedron, 1995, 51, 8555)

35

2-Amino-4-chlorophenol (ex Aldrich) (50g 0.35mol) was dissolved in 2.5 M hydrochloric acid (500ml), cooled to 0 °C and a solution of sodium nitrite (25.3g, 0.37mol) in water (50 ml) was slowly added over 20 minutes at 0-5 °C, stirred for 30 minutes, then a solution of potassium iodide (70g, 0.42 mol.) in water (100ml) was added slowly at 0 °C. The reaction mixture was then allowed

to warm to 10 °C over 3 hours. The product was then extracted with ethyl acetate (200ml), washed with 10% sodium bisulphite, water, and was dried over magnesium sulphate and evaporated down to dryness. The product was purified by column chromatography with 5% ethylacetate in hexane to give an orange solid. wt.62g. 70% yield.


5

Compound II: 2-Benzylxy-5-chloro-iodobenzene

4-Chloro-2-iodophenol (57g. 0.22M) was dissolved in acetonitrile (500mls), caesium carbonate (72.6g, 0.22M.) was added slowly giving rise to an exotherm (19-24° C) over 30 minutes. The 10 reaction mixture was then kept at 24°C for a further 5 hours. The reaction mixture was then stirred at 40 °C for 4 hours, then stirred at room temperature over night. The reaction mixture was filtered and evaporated down to a pink/brown solid. After trituration with water (200ml) the suspension was filtered and recrystallised from hexane (200ml) giving the title compound 50.2g, 65% yield. A second crop gave a further 22.7g. Total yield after drying 88%.

15 Rt=13.20 min.

Compound III: (2-Benzylxy-5-chlorophenyl)-boronic acid




(WO 01/19814 A2)

20 2-Benzylxy-5-chlorophenyl iodide (5g 0.0145 mol) in diethyl ether/tetrahydrofuran (100:30) was cooled to -100°C. n-Butyl lithium, 1.6M solution in hexanes (10mL, 0.016 mol) was added dropwise over 15min under nitrogen. The reaction mixture was then allowed to rise to -70°C for 1h. Triethylborate (9mL, 0.03 mol) was added dropwise under nitrogen. The cooling bath was then removed and the reaction mixture was stirred at room temperature overnight. The reaction mixture 25 was then quenched with 2N hydrochloric acid (40mL) and stirred vigorously at room temperature for 1h. The product was then extracted with ethyl acetate, dried over magnesium sulphate and evaporated down to an oil. Purification was carried out on a Biotage (90g cartridge) with ether / iso-hexane (50:50) to give the required product (wt; 2.8g i.e. 74% yield).

30

Compound IV: (2-Bromo-cyclopenten-1-enyl)-trimethylstannane



n-Butyllithium, 1.6M in hexanes, (58mL, 92.0mmol) in THF (50mL) was cooled under nitrogen to -75°C. 1,2-Dibromocyclopentene (10.00g, 44.3 mmol) in dry THF (10mL) was added dropwise over 5 ~10 minutes. The mixture was stirred at -75°C for a further 20 minutes and then allowed to reach 0°C. The reaction mixture was then re-cooled to -75°C and trimethyltin chloride (8.85g, 44.3 mmol) in THF (30mL) was added, under nitrogen, over ~10 minutes. After stirring at -75°C for 30 minutes the reaction was allowed to reach room temperature and then stirred for 2 hours. The reaction mixture was then evaporated down to an oil and partitioned between brine and 10 dichloromethane (100/200mL). After shaking thoroughly, the organic layer was dried (magnesium sulphate), filtered and evaporated to give an oil.(13.15g, ~80% pure).

¹H NMR (400MHz CDCl₃) 0.25 (9H, s), 1.91-2.2 (2H, m), 2.38-2.47 (2H, m), 2.64-2.73 (2H, m).

Compound V: 6-Bromopyridine-2-carboxylic acid methyl ester

15




6-Bromopyridine-2-carboxylic acid (6.000g) was heated in refluxing methanol (180mL) containing conc. sulphuric acid (2mL) for 4 hrs. The reaction mixture was then cooled to ~0°C and conc. ammonia (4.8mL) was added. The resulting solution was evaporated to give a white residue. This 20 white solid was partitioned between brine and dichloromethane (100/100mL). After thorough shaking the organic layer was dried (magnesium sulphate) and evaporated to give a white solid. (6.300g, 98%).

¹H NMR (400MHz, CDCl₃) 4.00 (3H, s), 7.66-7.74 (2H, m), 8.07-8.13 (1H, m).

25 Example 1: {2-[5-chloro-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

a) 3-(2-Bromocyclopent-1-enyl)-benzoic acid ethyl ester



1,2-Dibromocyclopentene (Ex Aldrich, 27,732-0) (5g, 0.0221 mol), (3-ethoxycarbonylphenyl) boronic acid (Ex Combiblocks inc. BB-2117-005) (4.26g, 0.0221 mol), Pd(0)[PPh₃]₄ (0.5g) and potassium carbonate (5g)

5 potassium carbonate (5g) were stirred at 80°C under nitrogen for 18h in dimethoxyethane (30mL).

The reaction mixture was then filtered through Kieselguhr and evaporated down to an oil.


Purification was carried out on a Biotage (90g column) using iso-hexane containing a gradient of dichloromethane (0-30%) to give the required product (wt: 1.15g i.e. 30% yield)

¹H NMR(400MHz, CDCl₃) 1.40 (3H, t, J=7Hz), 2.00-2.12 (2H, m), 2.75-2.94 (4H, m's), 4.39 (2H,

10 q, J=7Hz), 7.43 (1H, t, J=8Hz), 7.85 (1H, d, J=8Hz), 7.96 (1H, d, J=8Hz), 8.22 (1H, s).

LC/MS rt 3.82, [MH⁺] 295, 297.

b) 3-{2-[5-chloro-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid ethyl ester



15


3-(2-Bromocyclopent-1-enyl)-benzoic acid ethyl ester (0.148g, 0.0005 mol), Pd(0)[PPh₃]₄ (30mg), potassium carbonate (0.2g) and (2-benzyloxy-5-chlorophenyl) boronic acid (150mg, 0.0005 mol) in dimethoxyethane (5mL) were refluxed for 17h under nitrogen. The reaction mixture was then

20 filtered through Kieselghur and evaporated down to an oil. Purification was carried out on a Water's separation pack (10g) with dichloromethane/iso-hexane giving the product (85mg).

¹H NMR (400MHz, CDCl₃) 1.31 (3H, t, J=7Hz), 2.01-2.12 (2H, m), 2.81-2.88 (4H, m's), 4.28 (2H, q, J=8Hz), 4.93 (2H, s), 6.81 (1H, d, J=8Hz), 7.02, (1H, d, J=2Hz), 7.10-7.33 (8H, m's excess), 7.76-7.86 (2H, m).

25 LC/MS rt 4.21, [MH⁺] 433.

c) 3-{2-[5-chloro-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid



3-{2-[5-chloro-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid ethyl ester (80mg) was refluxed for 1h in methanol/2N sodium hydroxide (10:10mL). The reaction mixture

5 was then evaporated down to 3mL. 2N Hydrochloric acid (10mL) was added and the product extracted with dichloromethane (2x 10mL), dried over magnesium sulphate and evaporated down to an oil which solidified on standing (wt: 70mg).


¹H NMR (400MHz, CDCl₃) 2.00-2.18 (2H, m), 2.80-3.50 (4H, m's), 4.94 (2H, s), 6.82 (1H, d J=9Hz), 7.02 (1H, d, J=2Hz), 7.10-7.40 (8H, m's excess), 7.86 (1H, d, J=7Hz), 7.90 (1H, s).

10 LC/MS RT = 3.63min [MH⁺] 403, 404.

Example 2: 3-{2-[2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

a) 3-{2-[2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

15



3-(2-Bromo-cyclopent-1-enyl) benzoic acid ethyl ester (0.148g, 0.0005mol), tetrakis-triphenylphosphine palladium (0) (30mg), potassium carbonate (0.200g) and (2-benzyloxyphenyl)

20 boronic acid (0.110g, 0.5mmol) in dimethoxyethane (5mL) were refluxed for 17h under nitrogen.


The reaction mixture was then filtered through Keiselghur and evaporated down to an oil.

Purification was carried out on a Water's separation pack (10g) cartridge with dichloromethane/iso hexane giving the product (120mg).

¹H NMR (400MHz, CDCl₃) 1.30 (3H, t, J=7Hz), 2.01-2.13 (2H, m), 2.84-2.99 (4H, m's), 4.27 (2H,


25 q, J=7Hz), 5.00 (2H, s), 6.85 (1H, td, J=1Hz, J=7Hz), 6.92 (1H, d, J=8Hz), 7.02 (1H, d, J=7Hz), 7.11-7.34 (8H, m's excess), 7.76 (1H, d, J=8Hz), 7.85 (1H, s).

LC/MS RT = 4.09min.

b) 3-[2-[2-(benzyloxy)-phenyl]-cyclopent-1-enyl]-benzoic acid

5 3-[2-(2-Benzylxyphenyl)-cyclopent-1-enyl] benzoic acid ethyl ester (120mg) was refluxed for 1h in methanol/2N sodium hydroxide (10/10mL). The reaction mixture was then evaporated down to 3mL on a rotary evaporator. 2N Hydrochloric acid was added. The product was extracted with dichloromethane (2x 10mL), dried over magnesium sulphate and evaporated down to an oil which solidified on standing (wt: 100mg).


10 ^1H NMR (400MHz, CDCl_3) 2.01-2.13 (2H, m), 2.85-3.00 (4H, m's), 5.00 (2H, s), 6.86 (1H, t, $J=7\text{Hz}$), 6.92 (1H, d, $J=8\text{Hz}$), 7.02 (1H, dd, $J=2\text{Hz}$, $J=7\text{Hz}$), 7.12-7.35 (8H, m's excess), 7.82 (1H, d, $J=8\text{Hz}$), 7.91 (1H, s).
 LC/MS RT = 3.81min [MH⁺] 371, [MH⁻] 369.

15 **General Procedure 1**3-(2-Bromocyclopent-1-enyl)-benzoic acid ethyl ester

20 1,2-Dibromocyclopentene (Aldrich) (5.000g, 22.1mmol), (3-ethoxycarbonylphenyl) boronic acid (Combiblocks) (4.260g, 22.1mmol), tetrakis(triphenylphosphine)palladium(0) (0.500g) and potassium carbonate (5.000g) were stirred at 80°C under nitrogen for 18h in dimethoxyethane (30mL). The reaction mixture was then filtered through Kieselguhr and evaporated down to give an oil.

25 Purification by chromatography using iso-hexane containing a gradient of dichloromethane (0-30%) gave the required product (1.150g, 30% yield).

General Procedure 2


3-(2-Bromo-cyclopent-1-enyl)benzoic acid ethyl ester

5 (2-Bromo-cyclopent-1-enyl)trimethyl stannane (~80% pure) (13.150g, 43.7mmol), ethyl-3-iodobenzoate (24.000g, 87.4mmol), triphenylarsine (4.000g) and tris(dibenzylideneacetone)palladium (0) (1.500g), were heated in dimethylformamide (20mL) at 100°C, under nitrogen for 92 hours. The reaction mixture was then filtered through highflo, thoroughly washed with dichloromethane, reduced to an oil, and purified by chromatography with iso-hexane containing ether (2%-50%) to give the title compound (4.000g, 28%).

10 ¹H NMR (400MHz, CDCl₃), 1.40 (3H, t, J=7Hz), 2.00-2.21 (2H, m), 2.76-2.83 (2H, m), 2.80-2.91 (2H, m), 4.33-4.45 (2H, m), 7.43 (1H, t, J=8Hz), 7.83 (1H, d, J=8Hz), 7.92-7.98 (1H, d, J=8Hz), 8.20 (1H, s).

LC/MS [MH⁺] 297 Rt=3.87 min.

15

5-(2-Bromocyclopent-1-enyl)nicotinic acid ethyl ester

Prepared according to general procedure 2

20

(2-Bromocyclopent-1-enyl)trimethyl stannane (13.7g, 44.30 mmol)
 ethyl-5-bromonicotinate (14.0g, 60.0 mmol)
 tris(dibenzylideneacetone)palladium (0) (1.500g)
 triphenylarsine (4.0g)


25 dimethylformamide (20mL)

Heated at 100°C for 92 hours

Product (7.0g, 56%).

LC/MS (CF104055-1) [MH⁺] 298

¹H NMR (400MHz, CDCl₃), 1.42 (3H, t, J=7Hz), 2.06-2.16 (2H, m), 2.77-2.85 (2H, m), 2.86-2.93 (2H, m), 8.50 (1H, s), 9.00 (1H, d, J=2.2Hz), 9.15 (1H, d, J=2Hz).

6-(2-Bromocyclopent-1-enyl)pyridine-2-carboxilic acid methyl ester


5 Prepared using general procedure 2:

(2-Bromocyclopent-1-enyl)trimethylstannane (6.0g, 19.4 mmol)

6-bromopyridine-2-carboxylic acid methyl ester (6.0g, 26.0 mmol)

tris(dibenzylideneacetone)palladium (0) (1.0g)

triphenylarsine (2.0g) were heated at 115°C for 40 hrs in dimethylformamide (20mL). Product (2.7g). This oil was carried through the next stage without further purification.

10 LC/MS (CF105919-1) [MH⁺] 284 Rt=3.21min.**General Procedure 3**

15

3-{2-[5-chloro-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid ethyl ester3-(2-Bromocyclopent-1-enyl)-benzoic acid ethyl ester (148mg, 0.5 mmol),
20 tetrakis(triphenylphosphine)palladium (0) (30mg), potassium carbonate (0.20g) and (2-benzyloxy-5-chlorophenyl) boronic acid (150mg, 0.5 mmol) in dimethoxyethane (5mL) were refluxed for 17h under nitrogen. The reaction mixture was then filtered through Kieselghur and evaporated down to an oil. Purification was carried out on a Water's separation pack (10g) with dichloromethane/isohexane to give the product (85mg).25 LC/MS [MH⁺] 433 Rt=4.21min¹NMR (400MHz, CDCl₃) 1.31 (3H, t, J=7Hz), 2.01-2.12 (2H, m), 2.81-2.88 (4H, m), 4.28 (2H, q, J=7Hz), 4.93 (2H, s), 6.81 (1H, d, J=9Hz), 7.02 (1H, J=2Hz), 7.10-7.33 (8H, m), 7.76-7.86 (2H, m).3-{2-[2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid ethyl ester

30

Prepared using general procedure 3

3-(2-Bromo-cyclopent-1-enyl) Benzoic acid ethyl ester (148mg, 0.5 mmol)

tetrakis(triphenylphosphine)palladium (0) (30mg)

potassium carbonate (200mg)

(2-benzyloxyphenyl) boronic acid (110mg, 0.5 mmol)


5 dimethoxyethane (5mL) were refluxed for 17h under nitrogen.

Product (120mg).

LC/MS: Rt=4.09min.

¹H NMR (400MHz, CDCl₃) 1.30 (3H, t, J=7Hz), 2.01-2.13 (2H, m), 2.84-2.99 (4H, m), 4.28 (2H, q, J=7Hz), 5.00 (2H, s), 6.85 (1H, td, J=1Hz, J=7Hz), 6.92 (1H, d, J=8Hz), 7.02 (1H, dd, J=2Hz, J=7Hz),
10 7.11-7.34 (8H, m), 7.76 (1H, d, J=8Hz), 7.85 (1H, s).

3-{2-[5-Bromo-2-(methoxy)phenyl]-cyclopent-1-enyl}-benzoic acid ethyl ester



15

Prepared using general procedure 3

3-(2-Bromocyclopent-1-enyl)benzoic acid ethyl ester (1.00g, 3.40 mmol)

3-bromo-6-methoxyphenylboronic acid (1.656g, 7.20 mmol) tetrakis(triphenylphosphine)palladium (0) (2.7g) (200mg)

20 potassium carbonate (2.0g)

dimethoxyethane (10mL)


reflux 24 hours.

product (416mg, 35%).

¹H NMR (400MHz, CDCl₃) 1.34 (3H, t, J=7Hz), 2.03-2.13 (2H, m), 2.79-2.85 (2H, m), 2.92-2.98

25 (2H, m), 3.61 (3H, s), 4.31 (2H, q, J=6.5Hz), 6.73 (1H, d, J=9Hz), 7.13 (1H, d, J=2.5Hz), 7.16-7.25 (2H, m), 7.31 (1H, dd, J=2.5Hz, J=11Hz), 7.77-7.82 (1H, m), 7.85 (1H, s).

5-{2-[5-Chloro-2-(methoxy)phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester



30

Prepared by general procedure 3

5-(2-Bromocyclopent-1-enyl)nicotinic acid ethyl ester (1.480g, 5.0 mmol)

3-chloro-6-methoxyphenylboronic acid (1.490g, 8.0 mmol)

tetrakis(triphenylphosphine)palladium (0) (0.300g)

potassium carbonate (2.000g)

5 dimethoxyethane (20mL)

reflux 92 hrs


product (1.500g, 85%).

LC/MS [MH+] 358 Rt=3.73 min.

¹H NMR (400MHz, CDCl₃) 1.36 (3H, t, J=7Hz), 2.07-2.26 (2H, m), 2.82-2.88 (2H, m), 2.93-2.99

10 (2H, m), 3.63 (3H, s), 4.35 (2H, q, J=7Hz), 6.79 (1H, d, J=9Hz), 6.98 (1H, d, J=3Hz), 7.19 (1H, dd, J=3Hz, J=11Hz), 8.30 (1H, t, J=4Hz), 8.45 (1H, d, J=2Hz), 8.94 (1H, d, J=2Hz).

5-{2-[5-Bromo-2-(methoxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester



15

Prepared by general procedure 3

5-(2-Bromocyclopent-1-enyl)-nicotinic acid ethyl ester (2.000g, 6.7 mmol)

3-bromo-6-methoxyphenylboronic acid (2.300g, 10.0 mmol)

20 tetrakis(triphenylphosphine)palladium (0) (0.300g)

anhydrous potassium carbonate (2.500g)

dimethoxyethane (20mL)

reflux 24hrs


product (1.100g, 41%).

25 ¹H NMR (400MHz, CDCl₃) 1.36 (3H, t, J=7Hz), 2.06-2.16 (2H, m), 2.80-2.90 (2H, m) 2.91-2.99

(2H, m), 3.63 (3H, s), 4.35 (2H, q, J=7Hz), 6.74 (1H, d, J=4Hz), 7.13 (1H, d, J=3Hz), 7.33 (1H, dd, J=2Hz, J=9.5Hz), 8.03 (1H, t, J=2Hz), 8.45 (1H, d, J=2Hz), 8.94 (1H, d, J=2Hz).

LC/MS (CF105233-1) [MH+] 404 Rt=3.77min.

30 5-{2-[5-Trifluoromethyl-2-(methoxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester



Prepared by general procedure 3

5-(2-Bromocyclopent-1-enyl)nicotinic acid ethyl ester (1.480g, 5.0 mmol)

2-methoxy-5-trifluoromethylphenylboronic acid (1.750g, 8.0 mmol)

5 tetrakis(triphenylphosphine)palladium (0) (0.3000g)

potassium carbonate(2.0g)

dimethoxyethane (20mL)


reflux 24 hr

product (2.00g, 100%).

10 ¹H MNR (400MHz, CDCl₃) 1.34 (3H, t, J=7Hz), 1.90-2.18 (2H, m), 2.85-2.93 (2H, m), 2.94-2.32 (2H, m), 3.69 (3H, s), 4.33 (2H, q, J=7Hz), 6.93 (1H, d, J=8.5Hz), 7.27 (1H, d, J=4Hz), 7.50 (1H, dd, J=2Hz, J=9Hz), 8.00 (1H, t, J=8Hz), 8.43 (1H, d, J=3Hz), 8.94 (1H, d, J=3Hz).

LC/MS (CF104952-1) [MH⁺] 392 Rt=3.76min.

15 6-{2-[5-Chloro-2-(methoxy)phenyl]-cyclopent-1-enyl}-pyridine-2-carboxylic acid methyl ester



Prepared by general procedure 3

20 6-(2-Bromocyclopent-1-enyl)pyridine-2-carboxylic acid methyl ester (2.700g, ~60%, 9.5 mmol)

3-chloro-6-methoxyphenylboronic acid (1.800g, 10.0 mmol)

tetrakis(triphenylphosphine)palladium (0) (0.500g)

potassium carbonate (2.500g)

dimethoxyethane (20mL)

25 reflux 24 hrs


product (0.700g, ~74% pure).

LC/MS [MH⁺] 344 Rt=3.62.

General Procedure 4

30




3-{2-[5-Bromo-2-(hydroxy)-phenyl]-cyclopent-1-enyl}-benzoic acid


5 3-{2-[5-Bromo-2-(methoxy)-phenyl]-cyclopent-1-enyl}-benzoic acid ethyl ester (416mg, 10.0 mmol) in dichloromethane (5mL) was cooled under nitrogen to $\sim 40^{\circ}\text{C}$ and was treated with a molar solution of borontribromide in dichloromethane (20mL, 20.0 mmol). The reaction mixture was then allowed to reach room temperature and kept stirring over night. The reaction mixture was then quenched with ice/water (50/50mL) and more dichloromethane (30mL) was added. After 10 stirring vigorously for 1.5 hr, the organic layer was separated, dried (magnesium sulphate), evaporated down and chromatographed with 1%methanol in dichloromethane to give (300mg, 80%).

15 ^1H NMR (400MHz, CDCl_3) 2.08-2.19 (2H, m), 2.82-2.90 (2H, m), 3.00-3.08 (2H, m), 6.72 (1H, d, $J=4\text{Hz}$), 7.24-7.40 (4H, m), 7.94 (1H, d, $J=4\text{Hz}$), 7.99 (1H, s).

15 LC/MS [MH-] 359 Rt=3.74 min.

General Procedure 5

20 6-{2-[5-Chloro-2-(4-chloro-benzyloxy)-phenyl]-cyclopent-1-enyl}-pyridine-2-carboxylic acid 4-chlorobenzyl ester




25 6-{2-[5-Chloro-2-(hydroxy)-phenyl]-cyclopent-1-enyl}-pyridine-2-carboxylic acid (97mg, 0.30 mmol) was refluxed in 2-butanone (4mL) with 4-chlorobenzyl bromide (140mg, 0.70 mmol) and potassium carbonate (1.0g) under nitrogen for five hours. The reaction mixture was then filtered

through highflo, evaporated down to an oil and chromatographed on a Water's sep-pak (10g) with ether/iso-hexane (15/85) to give (160mg, 92%).

LC/MS [MH⁺] 556 Rt=5.5 min.

⁵ ¹H NMR (400MHz, CDCl₃) 2.03-2.12 (2H, m), 2.84-2.92 (2H, m), 3.06-3.14 (2H, m), 4.85 (2H, s), 5.33 (2H, s), 6.76 (1H, d, J=8Hz), 7.02-7.13 (5H, m), 7.24-7.29 (2H, m), 7.32-7.40 (4H, m), 7.47 (1H, t, J=8Hz), 7.81 (1H, d, J=2Hz).

6-{2-[5-Chloro-2-(4-fluorobenzyl)-phenyl]-cyclopent-1-enyl}-pyridine-2-carboxylic 4-fluorobenzyl ester



10

Prepared according to general procedure 5.


Product (150mg, 92%).

LC/MS (CF106348-1) [MH⁺] 532 Rt=4.27 min.


¹⁵ ¹H NMR (400MHz, CDCl₃) 2.02-2.11 (2H, m), 2.84-2.91 (2H, m), 3.06-3.13 (2H, m), 4.86 (2H, s), 5.34 (2H, s), 6.78 (1H, d, J=8Hz), 6.92-6.99 (2H, m), 7.01-7.16 (7H, m), 7.40-7.50 (3H, m), 7.81 (1H, d, J=8Hz).

General Procedure 6

20



5-{2-[5-Chloro-2-(hydroxy)-phenyl]cyclopent-1-enyl}-nicotinic acid ethyl ester



25

5-{2-[5-Chloro-2-(methoxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester (1.500g, 4.20 mmol) in dry dichloromethane (20mL) was cooled to -75°C. Boron tribromide, 1M solution in


DCM, (40mL, 40.0 mmol) was added and the reaction mixture stirred at -75°C for a further hour. The temperature of the reaction was then allowed to rise to -15°C and kept at -15°C for a further 2 hours, and was then quenched in ice/water (50g/50mL). More dichloromethane (60mL) was added and the resulting mixture was stirred vigorously for ~2hrs. The layers were separated and the 5 organic layer was washed with saturated sodium bicarbonate, dried (magnesium sulphate), filtered and reduced to an oil. The oil was then purified by chromatography to give the title compound (0.800g, 60%).

LC/MS [MH+] 344 Rt=3.56.

¹H NMR (400MHz, CDCl₃) 1.38 (3H, t, J=7Hz), 2.10-2.20 (2H, m), 2.86-2.95 (2H, m), 2.96-10 3.05 (2H, m), 4.38 (2H, q, J=7Hz), 6.74 (1H, d, J=8Hz), 7.03-7.12 (2H, m), 8.27 (1H, s), 8.53 (1H, s), 8.94 (1H, s).

5-{2-[5-Bromo-2-(hydroxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester

15




Prepared by general procedure 6

5-{2-[5-Bromo-2-(methoxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester (1.100g, 2.70 mol) dichloromethane (10mL)
20 boron tribromide (1 Molar solution in dichloromethane) (30mL) product (0.53g, 53%).
¹H NMR (400MHz, CDCl₃) 1.39 (3H, q, J=7Hz), 2.14-2.25 (2H, m), 2.90-3.10 (4H, m), 4.43 (2H, q, J=7Hz), 6.80 (1H, d, J=8Hz), 6.93 (1H, d, J=8Hz), 7.23-7.30 (1H, m), 8.60 (1H, s), 8.65 (1H, s), 8.93 (1H, s).
25 LC/MS [MH+] 390 Rt=3.58min.

5-{2-[5-Trifluoromethyl-2-(hydroxy)-phenyl]cyclopent-1-enyl}-nicotinic acid ethyl ester

30



Prepared by general procedure 6

5-{2-[5-Trifluoromethyl-2-(methoxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester (0.500g, 1.20 mmol)

dichloromethane (10mL)

boron tribromide (1M solution in dichloromethane) (20mL)


5 product (0.480g)

¹H NMR (400 MHz, CDCl₃) 1.36 (3H, t, J=7Hz), 2.13-2.20 (2H, m), 2.87-2.95 (2H, m), 2.97-3.07 (2H, m), 4.37 (2H, q, J=7Hz), 6.70 (1H, d, J=8Hz), 7.23-7.34 (2H, m), 8.17 (1H, s), 8.44 (1H, d, J=1.6Hz), 8.95 (1H, d, J=1.6Hz).

LC/MS [MH⁺] 378 Rt=3.60min.

10

6-{2-[5-Chloro-2-(hydroxy)-phenyl]-cyclopent-1-enyl}-pyridine-2-carboxylic acid methyl ester



15 prepared by general procedure 6

5-{2-[5-Chloro-2-(methoxy)-phenyl]-cyclopent-1-enyl}-pyridine-2-carboxylic acid methyl ester (0.700g, ~75% pure)

dichloromethane (5mL)

borontribromide (1M in dichloromethane) (10mL).

20 Two products isolated:

6-{2-[5-Chloro-2-(hydroxy)-phenyl]-cyclopent-1-enyl}-pyridine-2-carboxylic acid methyl ester (0.200g)

LC/MS [MH⁺] 330 Rt-3.45min.


25 ¹H NMR(400MHz, CDCl₃) 2.07-2.17 (2H, m), 2.85-2.93 (2H, m), 3.02-3.09 (2H, m), 3.97 (3H, s), 7.02 (1H, d, J=4.5Hz), 7.06 (1H, d, J=1.5Hz), 7.14 (1H, dd, J=1.5Hz, J=5.5Hz), 7.49 (1H, d, J=4Hz), 7.83 (1H, t, J=7.5Hz), 7.94 (1H, d, J=4Hz), 9.37 (1H, s).

6-{2-[5-Chloro-2-(hydroxy)-phenyl]-cyclopent-1-enyl}-pyridine-2-carboxylic acid (0.195g)

30 LC/MS [MH⁺] 315 Rt=3.08min


¹H NMR(400MHz, CDCl₃) 2.12-2.22 (2H, m), 2.87-2.96 (2H, m), 3.05-3.13 (2H, m), 6.95 (1H, d, J=9Hz), 7.06 (1H,d, J=2.5Hz), 7.18 (1H, dd, J=3Hz, J=11Hz), 7.47 (1H, d, J=8Hz), 7.87 (1H, t, J=8.5Hz), 8.03 (1H, d, J=7Hz).

35 General Procedure 7



Example 3: 3-{2-[5-bromo-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

5




3-{2-[5-Bromo-2-(hydroxy)-phenyl]-cyclopent-1-enyl}-benzoic acid (0.04g, 0.12mmol), benzyl bromide (0.038g, 0.22moles), potassium hydroxide (~0.15g), in dimethyl sulphoxide (1.5mL) were stirred at room temperature over 18hrs under nitrogen. The reaction mixture was then quenched with ice/water (10/10mL), stirred at room temperature for ~1.5hrs, acidified with 2N hydrochloric acid to pH~3 and extracted with dichloromethane. The organic extract was then dried (anhydrous sodium sulphate) and concentrated down to an oil and was then chromatographed on Water's Sep-Pak C18 cartridge (10g) giving (0.028g, 54%).

15 LC/MS [MH-] 449 Rt=4.19 min.

¹NMR (400MHz, CDCl₃) 2.03-2.12 (2H, m), 2.83-2.90 (2H, m), 2.91-2.97 (2H, m), 4.94 (2H, s), 6.77 (1H, d, J=9Hz), 7.14-7.23 (4H, m), 7.23-7.34 (5H, m), 7.85 (1H, d J=7.5Hz), 7.89 (1H, s).

Example 4: 3-{2-[5-Bromo-2-(4-Chlorobenzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

20




Prepared according to general procedure 7

Product (22mg, 31%)

25 LC/MS (CF104431-1) [MH-] 483 Rt=4.36 min.

Example 5: 3-{2-[5-Bromo-2-(4-fluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid




Prepared according to general procedure 7

5 Product (22mg, 32%)

LC/MS [MH-] 467 Rt=4.19 min.

Example 6: 3-{2-[5-Bromo-2-(3,4-dichlorobenzyl)oxy]phenyl}-cyclopent-1-enylbenzoic acid



10


Prepared according to general procedure 7

Product (18mg, 24%)

LC/MS [MH-] 517 Rt=4.53min ~60%pure

15

Example 7: 3-{2-[5-Bromo-2-(2,4-difluorobenzyl)oxy]phenyl}-cyclopent-1-enylbenzoic acid




20 Prepared according to general procedure 7

Product (27mg, 38%)

¹H NMR (400MHz, CDCl₃) 2.03-2.12 (2H, m), 2.79-2.86 (2H, m), 2.90-2.97 (2H, m), 4.92 (2H, s), 6.74-6.83 (3H, m), 7.08-7.28 (4H, m), 7.32 (1H, dd, J=3Hz, J=11Hz), 7.84-7.88 (2H, m).

25 **Example 8: 3-{2-[5-Bromo-2-(4-chloro-2-fluorobenzyl)oxy]phenyl}-cyclopent-1-enylbenzoic acid**




Prepared according to general procedure 7

5 Product (19mg, 26%)

LC/MS [MH-] 501 Rt=4.39 min.

¹H NMR (400MHz, CDCl₃) 2.03-2.13 (2H, m), 2.79-2.87 (2H, m), 2.90-2.98 (2H, m), 4.93 (2H, s), 6.77 (1H, d, J=8Hz), 7.03-7.28 (6H, m), 7.31 (1H, dd, J=3Hz, J=10Hz) 7.83-7.87 (2H, m).

10 Example 9: 3-{2-[5-Bromo-2-(4-methoxybenzyl)oxy]phenyl}-cyclopent-1-enyl-benzoic acid




Prepared according to general procedure 7

15 Product (14mg, 20%).


LC/MS [MH-] 479 Rt=4.15 min.

General Procedure 8




20

5-{2-[5-Chloro-2-(4-chlorobenzyl)oxy]phenyl}-cyclopent-1-enyl-nicotinic acid ethyl ester



5-{2-[5-Chloro-2-(hydroxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester (138mg, 0.43mmol) was treated with 4 chlorobenzyl bromide (0.130g, 60mmol) and potassium carbonate (1.000g) and 2-butanone (5mL) at reflux for 18hrs. Upon cooling, the mixture was filtered through highflo and reduced down to an oil. The product was purified using a Water's sep-pak cartridge (10g) to give (90mg, 44%)
 LC/MS [MH⁺] 468 Rt=4.19 min.

10 5-{2-[5-Chloro-2-(4-fluorobenzyl)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester



Prepared according to general procedure 8


15 Product (80mg, 41%)

LC/MS [MH⁺] 452 Rt=4.05 min.

¹H NMR (400MHz, CDCl₃) 1.35 (3H, t, J=7Hz), 2.05-2.14 (2H, m), 2.82 (2H, m), 2.89-2.96 (2H, m), 4.34 (2H, q, J=7Hz), 4.86 (2H, s), 6.83 (1H, d, J=9Hz), 6.94-7.20 (6H, m), 7.94 (1H, t, J=8Hz), 8.43 (1H, d, J=4Hz), 8.92 (1H, d, J=4Hz).

20

5-{2-[5-Chloro-2-(3,4-dichlorobenzyl)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester




25 Prepared according to general procedure 8

Product (10mg, 45%)

LC/MS [MH⁺] 504 Rt=4.32 min.5-{2-[5-Chloro-2-(2,4-difluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester

5




Prepared according to general procedure 8

Product (105mg, 51%)

LC/MS [MH⁺] 470 Rt=4.07 min.

10 ¹H NMR (400MHz, CDCl₃) 1.36 (3H, t, J=7Hz), 2.04-2.13 (2H, m), 2.80-2.88 (2H, m), 2.88-2.96 (2H, m), 4.35 (2H, q, J=7Hz), 4.92 (2H, s), 6.74-6.84 (2H, m), 6.87 (1H, d, J=9Hz), 7.04 (1H, d, J=3Hz), 7.08-7.17 (1H, q, J=8Hz), 7.19 (1H, dd, J=3.5Hz, J=10Hz), 7.94 (1H, t, J=4Hz), 8.40 (1H, d, J=2Hz), 8.92 (1H, d, J=2Hz).

15 5-{2-[5-Chloro-2-(4-chloro-2-fluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester

Prepared according to general procedure 8


20 Product (90mg, 42%)

LC/MS [MH⁺] 486 Rt=4.20 min.

¹H NMR (400MHz, CDCl₃) 1.35 (3H, t, J=7Hz), 2.05-2.14 (2H, m), 2.81-2.89 (2H, m), 2.89-2.97 (2H, m), 4.34 (2H, q, J=7Hz), 4.93 (2H, s), 6.86 (1H, d, J=9Hz), 7.02-7.12 (4H, m), 7.19 (1H, dd, J=3Hz, J=11Hz), 7.95 (1H, t, J=4Hz), 8.43 (1H, d, J=2Hz), 8.92 (1H, d, J=1Hz).

25

5-{2-[5-Chloro-2-(4-methoxybenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester




Prepared according to general procedure 8

Product (95mg, 47%)

LC/MS [MH⁺] 464 Rt=4.02 min.

5

5-{2-[5-Bromo-2-(4-chlorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester




10 Prepared according to general procedure 8

Product (16mg, 16%).

LC/MS [MH⁺] 514 Rt=4.22min.

¹H NMR (CDCl₃) 1.36 (3H, t, J=7.5Hz), 2.05-2.15 (2H, m), 2.82-2.89 (2H, m), 2.89-2.96 (2H, m), 4.30-4.39 (2H, q, J=7.5Hz), 4.86 (2H, s), 6.76 (1H, d, J=8Hz), 7.08 (1H, d, J=7.5Hz), 7.19 (1H, d, J=2Hz), 7.23-7.34 (4H, m), 7.95 (1H, s), 8.43 (1H, s), 8.92 (1H, s).

5-{2-[5-Bromo-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester




20 Prepared according to general procedure 8

Product (16mg, 17%)

LC/MS [MH⁺] 480 Rt=4.09 min.

¹H NMR (400MHz, CDCl₃) 1.34 (3H, t, J=8Hz), 2.05-2.14 (2H, m), 2.83-2.90 (2H, m), 2.90-2.97 (2H, m), 4.35 (2H, q, J=8Hz), 4.92 (2H, s), 6.79 (1H, d, J=8Hz), 7.14-7.20 (3H, m), 7.23-7.33 (4H, m), 7.90 (1H, s), 8.45 (1H, s), 8.92 (1H, s).

5-[2-[5-Bromo-2-(4-fluorobenzyl)oxy]-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester


5 Prepared according to general procedure 8

Product (14mg, 15%).

LC/MS [MH⁺] 498 Rt=4.09 min.

¹H NMR (400MHz, CDCl₃) 1.36 (3H, t, J=7Hz), 2.04-2.13 (2H, m), 2.82-2.89 (2H, m), 2.89-2.96 (2H, m), 4.35 (2H, q, J=7Hz), 4.86 (2H, s), 6.78 (1H, d, J=7.5Hz), 6.98 (2H, t, J=7.5Hz), 7.08-7.16 (2H, m), 7.19 (1H, s), 7.31 (1H, d, J=9Hz), 7.94 (1H, s), 8.44 (1H, s), 8.92 (1H, s).

10

5-[2-[5-Bromo-2-(2,4-difluorobenzyl)oxy]-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester

15


Prepared according to general procedure 8

Product (44mg, 44%)

LC/MS [MH⁺] 516 Rt=4.10 min.

¹H NMR (400 MHz, CDCl₃) 1.36 (3H, t, J=7Hz), 2.03-2.13 (2H, m), 2.80-2.88 (2H, m), 2.87-2.96 (2H, m), 4.34 (2H, q, J=7Hz), 4.91 (2H, s), 7.74-8.85 (3H, m), 7.08-7.16 (1H, bq, J=7.5Hz), 7.18 (1H, d, J=2Hz), 7.30-7.35 (1H, m), 7.95 (1H, s), 8.42 (1H, s), 8.92 (1H, s).

20

5-[2-[5-Bromo-2-(4-chloro-2-fluorobenzyl)oxy]-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester

25


Prepared according to general procedure 8

Product (41mg, 41%).

LC/MS [MH⁺] 532 t=4.24 min.

5 ¹H NMR (400MHz, CDCl₃) 1.36 (3H, t, J=6.5Hz), 2.05-2.14 (2H, m), 2.80-2.89 (2H, m), 2.89-2.97 (2H, m), 4.36 (2H, m), 4.93 (2H, s), 6.80 (1H, d, J=7Hz), 7.03-7.21 (4H, m), 7.33 (1H, d, J=6.5Hz), 7.95 (1H, s), 8.43 (1H, s), 8.92 (1H, s).

5-{2-[5-Bromo-2-(cyclohexylmethoxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester



10

Prepared according to general procedure 8


Product (53mg, 56%)

LC/MS [MH⁺] 486 Rt=4.47 min.

15 ¹H NMR (400MHz, CDCl₃) 0.89 (3H, m) 1.03-1.28 (4H, m), 1.36 (3H, t, J=7Hz), 1.50-1.72 (4H, m), 2.05-2.15 (2H, m), 2.79-2.88 (2H, m), 2.88-2.98 (2H, m), 3.62 (2H, d, J=6Hz), 4.35 (2H, q, J=7Hz), 6.72 (1H, d, J=8Hz), 7.10 (1H, s), 7.28-7.33 (1H, m), 8.2 (1H, s), 8.45 (1H, s), 8.93 (1H, s).

5-{2-[5-Trifluoromethyl-2-(4-Chlorobenzyl)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester

20




Prepared according to general procedure 8

Product (19mg, 14%).

25 ¹H NMR (400MHz, CDCl₃) 1.33 (3H, t, J=7Hz), 2.08-2.17 (2H, m), 2.86-2.98 (4H, m), 4.33 (2H, q, J=7Hz), 4.93 (2H, s), 6.94 (1H, d, J=4.3Hz), 7.09 (2H, d, J=8Hz), 7.24-7.36 (3H, m), 7.48 (1H, dd, J=2Hz, J=10Hz), 7.93 (1H, d, J=4Hz), 8.41 (1H, d, J=2Hz), 9.92 (1H, d, J=2Hz).

5-{2-[5-Trifluoromethyl-2-(4-fluorobenzyl)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester




Prepared according to general procedure 8

Product (29mg, 22%)

5 LC/MS [MH⁺] 486 Rt=4.05 min.

¹H NMR (400MHz, CDCl₃) 1.33 (3H, t, J=7Hz), 2.06-2.16 (2H, m), 2.80-2.98 (4H, m), 4.33 (2H, q, J=7.5Hz), 4.92 (2H, s), 6.93-7.03 (3H, m), 7.10-7.16 (2H, m), 7.34 (1H, d, J=2Hz), 7.49 (1H, dd, J=3Hz), 7.92 (1H, t, J=2Hz), 8.40 (1H, d, J=2Hz), 8.92 (1H, d, J=4Hz).

10 5-{2-[5-Trifluoromethyl-2-(2,4-difluorobenzyl)oxy]-phenyl}-cyclopent-1-enyl-nicotinic acid ethyl ester



15 Prepared according to general procedure 8


Product (42mg, 31%).

LC/MS [MH⁺] 504 Rt=4.07 min.

¹H NMR (400MHz, CDCl₃) 1.33 (3H, t, J=7.2Hz), 2.06-2.16 (2H, m), 2.83-2.91 (2H, m), 2.91-2.98 (2H, m), 4.33 (2H, q, J=7Hz), 4.99 (2H, s), 6.76-6.84 (2H, m), 7.01 (1H, d, J=9Hz), 7.12 (1H, q, J=8Hz), 7.33 (1H, d, J=2Hz), 7.51 (1H, dd, J=2 Hz, J=10 Hz), 7.92 (1H, t, J=4Hz), 8.40 (1H, d, J=2Hz), 8.92 (1H, d, J=2Hz).

5-{2-[5-Trifluoromethyl-2-(4-chloro-2-fluorobenzyl)oxy]-phenyl}-cyclopent-1-enyl-nicotinic acid ethyl ester

25




Prepared according to general procedure 8

Product (47mg, 35%).

¹H NMR (400MHz, CDCl₃) 1.33 (3H, t, J=7Hz), 2.06-2.17 (2H, m), 2.84-2.92 (2H, m), 2.92-2.99

5 (2H, m), 4.33 (2H, q, J=7Hz), 5.00 (2H, s), 6.99 (1H, d, J=8Hz), 7.04-7.12 (3H, m), 7.33 (1H, d, J=2Hz), 7.51 (1H, dd, J=3Hz), 7.92 (1H, t, J=4Hz), 8.41 (1H, d, J=2Hz), 8.92 (1H, d, J=2Hz).

5-[2-[5-Trifluoromethyl-2-(cyclohexylmethoxy)-phenyl]-cyclopent-1-enyl]-nicotinic acid ethyl ester



10


Prepared according to general procedure 8

Product (46mg, 36%)

LC/MS [MH⁺] 474 Rt=4.41 min.

15

6-[2-[5-Chloro-2-(2,4-difluorobenzyl)-phenyl]-cyclopent-1-enyl]-pyridine-2-carboxylic acid methyl ester



Prepared according to general procedure 8


20 Product (124mg, 90%).

LC/MS [MH⁺] 456 Rt=4.01min

¹H NMR (400MHz, CDCl₃) 2.03-2.12 (2H, m), 2.83-2.90 (2H, m), 3.06-3.14 (2H, m), 3.93 (3H, s), 4.93 (2H, s), 6.74-6.83 (2H, m), 6.85 (1H, d, J=9Hz), 7.01-7.08 (2H, m), 7.13-7.20 (2H, m), 7.48 (1H, t, J=8Hz), 7.83 (1H, d, J=8Hz).

25

6-[2-[5-Chloro-2-(4-chloro-2-fluorobenzyl)-phenyl]-cyclopent-1-enyl]-pyridine-2-carboxylic acid methyl ester




Prepared according to general procedure 8

Product (135mg, 94%)

5 LC/MS (CF106321-1) [MH⁺] 472 Rt=4.15 min.

¹H NMR (400MHz CDCl₃) 2.03-2.12 (2H, m), 2.84-2.9 (2H, m), 3.07-3.14 (2H, m) 3.93 (3H, s), 4.93 (2H, s), 6.83 (1H, d, J=8Hz), 7.01-7.15 (5H, m), 7.15-7.20 (1H, dd, J=3 Hz, J=11Hz), 7.48 (1H, t, J=7.5Hz), 7.83 (1H, d, J=8Hz).

10 General Procedure 9: Ester hydrolysis



Example 1: 3-{2-[5-chloro-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

15

3-{2-[5-chloro-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid ethyl ester (80mg) was refluxed for 1h in methanol/2N sodium hydroxide (10:10mL). The reaction mixture was then evaporated down to 3mL. 2N Hydrochloric acid (10mL) was added and the product extracted with dichloromethane (2x 10mL), dried (magnesium sulphate) and evaporated to give an oil which

20 solidified on standing (70mg).

LC/MS [MH⁻] 403 Rt = 3.63min

Example 2: 3-[2-(2-Benzyl-phenyl)-cyclopent-1-enyl]-benzoic acid


25 Prepared according to general procedure 9

Product (100mg).

LC/MS [MH⁻] 369 Rt = 3.81min.

General Procedure 10

30


Example 10: 5-{2-[5-Chloro-2-(4-chlorobenzylxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid

5 5-{2-[5-Chloro-2-(4-chlorobenzylxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid ethyl ester (90mg) was hydrolysed in methanol (3 mL) and 2N sodium hydroxide (2mL) at 60°C with stirring for 2 hrs. The reaction mixture was then reduced down to ~ 1mL, diluted with water (10mL) and treated with a few drops of glacial acetic acid to make the solution ~pH5. The product was then extracted twice with dichloromethane (10mL) dried (magnesium sulphate), and evaporated to give the title
 10 compound (75mg).

LC/MS [MH+] 440 Rt=4.22min.

Example 11: 5-{2-[5-Chloro-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid

15




Prepared according to general procedure 10

Product (95mg, yield).

1 ¹H NMR (400MHz, CDCl₃) 2.06-2.16 (2H, m), 2.85-2.99 (4H, m), 4.93 (2H, s), 6.85 (1H, d, J=8Hz), 7.4 (1H, d, J=3Hz), 7.13-7.22 (3H, m), 7.22-7.34 (3H, m), 8.65 (1H, t, J=4Hz), 8.49 (1H, d, J=2Hz), 9.01 (1H, d, J=2Hz).

Example 12: 5-{2-[5-Chloro-2-(4-fluorobenzylxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid




Prepared according to general procedure 10

(60mg, 81%)

5 LC/MS [MH⁺] 424 Rt=3.99 min.

¹H NMR (400MHz, CDCl₃) 2.06-2.16 (2H, m), 2.84-2.98 (4H, m), 4.86 (2H, s), 6.83 (1H, d, J=7.5Hz), 6.99 (2H, t, J=7.5Hz), 7.65 (1H, d, J=2Hz), 7.1-7.2 (3H, m), 8.05 (1H, s), 8.49 (1H, b.s), 9.02 (1H, b.s).

10 Example 13: 5-{2-[5-Chloro-2-(3,4-dichlorobenzyl)oxy]-phenyl}-cyclopent-1-enyl}-nicotinic acid




15 Prepared according to general procedure 10

Product (87mg, 92%)

LC/MS [MH⁺] 476 Rt=4.43 min.

20 Example 14: 5-{2-[5-Chloro-2-(2,4-difluorobenzyl)oxy]-phenyl}-cyclopent-1-enyl}-nicotinic acid



Prepared according to general procedure 10


Product (95mg, 96%)

LC/MS [MH⁺] 442 Rt=4.00min.

15 ¹H NMR (400MHz, CDCl₃) 2.50-2.15 (2H, m), 2.81-2.89 (2H, m), 2.89-2.98 (2H, m), 4.92 (2H, s), 6.74-6.9 (3H, m), 7.05 (1H, d, J=2Hz), 7.11-7.22 (2H, m), 8.05 (1H, s), 8.47 (1H, s), 9.05 (1H, m).

Example 15: 5-{2-[5-Chloro-2-(4-chloro-2-fluorobenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid

10



Prepared according to general procedure 10


Product (75mg, 89%).

LC/MS [MH⁺] 458 Rt=4.22 min.

15 ¹H NMR (400MHz, CDCl₃) 2.06-2.16 (2H, m), 2.83-2.91 (2H, m), 2.91-2.92 (2H, m), 4.93 (2H, s), 6.86 (1H, d, J=8Hz), 7.03-7.15 (4H, m), 7.18 (1H, dd, J=3Hz, J=9.5Hz), 8.05 (1H, s), 8.48 (1H, d, J=2Hz), 9.1 (1H, s).

20

Example 16: 5-{2-[5-Chloro-2-(4-methoxybenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid




Prepared according to general procedure 10

Product (78mg, 87%).

25 LC/MS [MH⁺] 436 Rt=3.92 min.

Example 17: 5-{2-[5-Bromo-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid



Prepared according to general procedure 10


Product (11mg, 73%).

5 LC/MS [MH⁺] 450 Rt=4.06 min

¹H NMR (400MHz, CDCl₃) 2.06-2.15 (2H, m), 2.84-2.98 (4H, m), 4.93 (2H, s), 6.80 (1H, d, J=8Hz), 7.15-7.21 (3H, m), 7.23-7.34 (4H, m), 8.05 (1H, s), 8.49 (1H, s), 8.99 (1H, s).

Example 18: 5-{2-[5-Bromo-2-(4-chlorobenzyl)oxy]phenyl}-cyclopent-1-enyl-nicotinic acid

10




Prepared according to general procedure 10

Product (40mg, 70%)

15 LC/MS [MH⁺] 486 Rt=4.27 min.

¹H NMR (400MHz, CDCl₃) 2.06-2.16 (2H, m), 2.84-2.92 (2H, m), 2.92-2.98 (2H, m), 4.86 (2H, s), 6.76 (1H, d, J=8Hz), 7.10 (2H, d, J=8Hz), 7.21 (1H, s), 7.24-7.36 (3H, m), 8.03 (1H, s), 8.48 (1H, s), 8.99 (1H, s).

20 **Example 19: 5-{2-[5-bromo-2-(4-fluorobenzyl)oxy]phenyl}-cyclopent-1-enyl-nicotinic acid**




Prepared according to general procedure 10

Product (19mg, 76%)

LC/MS (CF105499-1) [MH⁺] 470 Rt=4.05min

5 ¹H NMR (400MHz, CDCl₃) 2.06-2.15 (2H, m), 2.83-2.97 (4H, m), 4.86 (2H, s), 6.78 (1H, d, J=8Hz), 6.98 (2H, t, J=7Hz), 7.10-7.17 (2H, m), 7.20 (1H, s), 7.31 (1H, dd, J=2Hz, J=10Hz), 8.02 (1H, s), 8.48 (1H, s), 8.99 (1H, s).

10 Example 20: 5-{2-[5-Bromo-2-(2,4-difluorobenzyl)-phenyl]-cyclopent-1-enyl}-nicotinic acid



Prepared according to general procedure 10


15 Product (3mg, 75%)

LC/MS [MH⁺] 4.88 Rt=4.06 min.

¹H NMR (400MHz, CDCl₃) 2.05-2.15 (2H, m), 2.81-2.90 (2H, m), 2.90-2.98 (2H, m), 4.93 (2H, s), 6.76-6.87 (3H, m), 7.10-7.23 (2H, m), 7.3-7.36 (1H, d, J=9Hz), 8.04 (1H, s), 8.48 (1H, s), 9.00 (1H, s).

20

Example 21: 5-{2-[5-Bromo-2-(4-chloro-2-fluorobenzyl)-phenyl]-cyclopent-1-enyl}-nicotinic acid




25 Prepared according to general procedure 10

Product (3mg, 80%)

LC/MS [MH⁺] 505 Rt=4.29 min.

¹H NMR (400MHz, CDCl₃) 2.06-2.15 (2H, m), 2.82-2.90 (2H, m), 2.90-2.98 (2H, m), 4.93 (2H, s), 6.81 (1H, d, J=8Hz), 7.03-7.18 (3H, m), 7.19 (1H, s), 7.33 (1H, d, J=8Hz), 8.03 (1H, s), 8.47 (1H, s), 8.99 (1H, s).

5 Example 22: 5-{2-[5-Bromo-2-(4-methoxybenzyloxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid



Prepared according to general procedure 10


10 Product (12mg, 92%)

LC/MS [MH⁺] 481 Rt=4.01 min.

¹H NMR (400MHz, CDCl₃) 2.04-2.14 (2H, m), 2.83-2.96 (4H, m), 3.76 (3H, s), 4.83 (2H, s), 6.77-6.86 (3H, m), 7.08 (2H, d, J=8Hz), 7.18 (1H, d, J=2.6Hz), 7.30 (1H, dd, J=2Hz, J=4Hz), 8.02 (1H, s), 8.46 (1H, s), 8.99 (1H, s).

15

Example 23: 5-{2-[5-Bromo-2-(cyclohexylmethoxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid




20 Prepared according to general procedure 10

Product (48mg, 96%)

LC/MS [MH⁺] 458 Rt=4.60min.

Example 24: 5-{2-[5-Trifluoromethyl-2-(4-chlorobenzyl)-phenyl]-cyclopent-1-enyl}-nicotinic acid




Prepared according to general procedure 10

Product (16mg, 89%)

5 LC/MS [MH⁺] 474 Rt=4.11 min.

¹H NMR (400MHz, CDCl₃) 2.08-2.18 (2H, m), 2.86-2.99 (4H, m), 4.93 (2H, s), 6.95 (1H, d, J=8Hz), 7.11 (2H, d, J=8Hz), 7.23-7.37 (3H, m), 7.48 (1H, dd, J=2Hz, J=9Hz), 8.1 (1H, s), 8.44 (1H, s), 8.97 (1H, s).

10 Example 25: 5-{2-[5-Trifluoromethyl-2-(4-fluorobenzyl)-phenyl]-cyclopent-1-enyl}-nicotinic acid



15 Prepared according to general procedure 10


Product (22mg, 81%)

LC/MS [MH⁺] 458 Rt=3.93 min.

¹H NMR (400MHz, CDCl₃) 2.07-2.17 (2H, m), 2.87-2.90 (4H, m), 4.93 (2H, s) 6.93-7.04 (3H, m), 7.11-7.18 (2H, m), 7.35 (1H, s), 7.48 (1H, d, J=8Hz), 8.03 (1H, s), 8.4 (1H, s) 8.97 (1H, s).

20

Example 26: 5-{2-[5-Trifluoromethyl-2-(2,4-difluorobenzyl)-phenyl]-cyclopent-1-enyl}-nicotinic acid




Prepared according to general procedure 910

Product (35mg, 88%)

5 LC/MS [MH⁺] 476 Rt=3.95 min.

¹H NMR (400MHz, CDCl₃) 1.70-1.83 (2H, m), 2.5-2.78 (4H, m), 4.88 (2H, s), 6.65-6.75 (2H, m), 6.81-6.88 (1H, m), 7.03-7.12 (2H, m), 7.38-7.35 (1H, d, J=9Hz), 7.86 (2H, s) 8.68 (1H, s).

10 **Example 27: 5-{2-[5-Trifluoromethyl-2-(4-chloro-2-fluorobenzyl)oxy}-phenyl]-cyclopent-1-enyl}-nicotinic acid**




Prepared according to general procedure 10

15 Product (38mg, 86%)

LC/MS [MH⁺] 490 Rt=4.11 min.

¹H NMR(400MHz, CDCl₃) 2.07-2.17 (2H, m), 2.85-2.99 (4H, m), 5.10 (2H, s), 6.99 (1H, d, J=8Hz), 7.05-7.16 (3H, m), 7.34 (1H, d, J=2Hz), 7.46-7.54 (1H, m), 8.04 (1H, s), 8.43 (1H, s), 8.96 (1H, s).

20 **Example 28: 5-{2-[5-Trifluoromethyl-2-(cyclohexylmethoxy)-phenyl]-cyclopent-1-enyl}-nicotinic acid**




Prepared according to general procedure 10

Product (37mg, 86%)

LC/MS (CF105897-1) [MH⁺] 446.1 Rt=4.36 min.

5 Example 29: 6-{2-[5-Chloro-2-(2,4-difluorobenzyl)oxy]-phenyl}-cyclopent-1-enyl}-pyridine-2-carboxylic acid



Prepared according to general procedure 10


10 Product (92mg, 76%)

LC/MS [MH⁺] 442 Rt=3.84 min

¹H NMR (400MHz, CDCl₃) 2.06-2.16 (2H, m), 2.84-2.92 (2H, m), 2.97-3.5 (2H, m), 4.93 (2H, s), 6.71-6.78 (2H, m), 6.95 (1H, d, J=8Hz) 7.05-7.13 (2H, m), 7.23-7.30 (2H, m), 7.71 (1H, t, J=7.5Hz), 7.91 (1H, d, J=8Hz).

15

Example 30: 6-{2-[5-Chloro-2-(4-chloro-2-fluorobenzyl)oxy]-phenyl}-cyclopent-1-enyl}-pyridine-2-carboxylic acid



20


Prepared according to general procedure 10

Product (112mg, 85%)

LC/MS [MH⁺] 458 Rt=4.02 min

¹H NMR (400MHz, CDCl₃) 2.07-2.17 (2H, m), 2.85-2.92 (2H, m), 2.98-3.05 (2H, m), 4.93 (2H, s), 6.93 (1H, d, J=8Hz) 6.98-7.08 (3H, m), 7.11 (1H, d, J=3Hz), 7.24-7.30 (2H, m), 7.72 (1H, t, J=8Hz), 7.90 (1H, d, J=7Hz).

Example 31: 6-{2-[5-Chloro-2-(4-chlorobenzoyloxy)-phenyl]-cyclopent-1-enyl}-pyridine 2-carboxylic acid



5 Prepared according to general procedure 10


Product (70.0mg, 56%)

LC/MS [MH⁺] 440 Rt=3.99 min.

¹H NMR (400MHz CDCl₃) 2.07-2.17 (2H, m), 2.87-2.93 (2H, m), 2.98-3.05 (2H, m) 4.87 (2H, s), 6.89 (1H, d, J=8Hz), 7.05 (1H, d, J=7.5Hz), 7.1 (1H, d, J=3Hz), 7.20-7.35 (5H, m) 7.15 (1H, t, J=7.5Hz), 7.91 (1H, d, J=7Hz).

10

Example 32: 6-{2-[5-Chloro-2-(4-fluorobenzoyloxy)-phenyl]-cyclopent-1-enyl}-pyridine 2-carboxylic acid



15

Prepared according to general procedure 10

Product (60mg, 50%)

LC/MS [MH⁺] 424 Rt=3.80 min.


¹H NMR (400MHz CDCl₃) 2.07-2.16 (2H, m), 2.86-2.93 (2H, m), 2.98-3.05 (2H, m), 4.87 (2H, s), 6.87-6.97 (2H, m), 7.01-7.12 (4H, m), 7.21-7.37 (2H, m), 7.71 (1H, t, J=7Hz), 7.91 (1H, d, J=7.5Hz).

20

25

Example 33: 3-{2-[5-methylsulfonyl-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid


a) 2-Methoxy-5-methylthiophenylboronic acid



1.6M butyllithium in hexanes (3.5 ml, 5.6 mmol) was added dropwise to a stirred solution of 2-bromo-4-methylthioanisole (1.165g, 5 mmol) in anhydrous tetrahydrofuran (30 ml) at -100°C under nitrogen and stirred for 5 minutes then warmed to -78°C for 1 hour. Triisopropyl borate (2.82 g, 15 mmol) was added dropwise and the mixture allowed to warm to room temperature. Hydrochloric acid (30ml, 30 mmol) were added and the mixture stirred vigorously for 1 hour. The organic phase was separated, washed with brine, dried (MgSO_4), evaporated to dryness and the residue purified on Biotage using ethyl acetate/ iso-hexane (3:7) to yield the title compound as a white solid. (616 mg, 62%).

¹H NMR (CDCl_3) δ : 2.47 (3H, s), 3.91 (3H, s), 5.82 (2H, s), 6.87 (1H, d, $J=8\text{Hz}$), 7.41 (1H, dd,

b) 3-{2-[5-methylsulfanyl-2-(methoxy)-phenyl]-cyclopent-1-enyl}-benzoic acid ethyl ester




A mixture of 2-methoxy-5-methylthiophenylboronic acid (594 mg, 3 mmol), 3-(2-bromo-cyclopent-1-enyl)-benzoic acid ethyl ester (885 mg, 3 mmol), potassium carbonate (2.76 g, 20 mmol) and tetrakis(triphenylphosphine)palladium(0) (347 mg, 0.3 mmol) was stirred and heated in 1:1 toluene/ethanol (30 ml) at 90°C under nitrogen for 4 hours. After cooling the mixture was diluted with diethyl ether/water and the organic phase dried (MgSO_4), evaporated to dryness and the residue purified on Biotage using ethyl acetate/iso-hexane (1:19) to yield the title compound as a white solid. (790 mg, 71%).

¹H NMR (CDCl_3) δ : 1.33 (3H, t, J =7Hz), 2.09 (2H, m), 2.27 (3H, s), 2.87 (2H, m), 2.96 (2H, m), 3.66 (3H, s), 4.32, (2H, q, J =7Hz), 6.80-7.28 (5H, m), 7.77-7.85 (2H, m).

LC/MS t =4.03, [MH⁺] 369.1.

c) 3-[2-[5-methylsulfanyl-2-(hydroxy)-phenyl]-cyclopent-1-enyl]-benzoic acid



A mixture of sodium methanethiolate (700 mg, 10 mmol) and 3-{2-[5-methylsulfanyl-2-(methoxy-)-phenyl]-cyclopent-1-enyl}-benzoic acid ethyl ester (720 mg, 1.96 mmol) in dimethylformamide (15 ml) was stirred and heated at 120°C under nitrogen for 5 hours. After cooling the mixture was


5 diluted with diethyl ether/water and the aqueous phase separated and acidified with hydrochloric acid then extracted with diethyl ether. The organic phase was dried (MgSO_4), evaporated to dryness and the residue triturated with diethyl ether/ iso-hexane to yield the title compound as a white solid, (437 mg, 68%).

10 ^1H NMR (CDCl_3) δ : 2.14 (2H, m), 2.88 (2H, t, $J=8\text{Hz}$), 3.05, (2H, $J=8\text{Hz}$), 4.90 (1H, br s), 6.78, (1H, d, $J=7\text{Hz}$), 7.16-7.39 (4H, m), 7.92 (1H, d, $J=8\text{Hz}$), 7.99 (1H, s).

LC/MS $t=3.54$, $[\text{MH}^-]$ 325.

Standard alkylation procedure

15 d) 3-{2-[5-methylsulfanyl-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid benzyl ester




A stirred mixture of 3-{2-[5-methylsulfanyl-2-(hydroxy)-phenyl]-cyclopent-1-enyl}-benzoic acid (65 mg, 0.2 mmol), potassium carbonate (138 mg, 1 mmol) and benzyl bromide (75 mg, 0.44 mmol)

20 in acetone (4 ml) was refluxed for 16 hours then cooled and diluted with diethyl ether/water. The organic phase was dried (MgSO_4), evaporated to dryness and purified using Biotage with ethyl acetate/iso-hexane (1:19) to yield the title compound as a colourless gum. (85 mg, 84%).

^1H NMR (CDCl_3) δ : 2.06 (2H, m), 2.24 (3H, s), 2.90 (4H, m), 4.92 (2H, s), 5.28 (2H, s), 6.78 (1H, d, $J=9\text{Hz}$), 6.97, d, $J=2\text{Hz}$), 7.09-7.38 (13H, m), 7.81 (1H, d, $J=8\text{Hz}$), 7.86 (1H, s).

25 LC/MS $t=4.43$, $[\text{MH}^+]$ 507.1.


Standard hydrolysis procedure**e) 3-{2-[5-methylsulfonyl-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid**

5 A solution of 3-{2-[5-methylsulfonyl-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid benzyl ester (30 mg, 0.059 mmol) in ethanol (5 ml) and 2M sodium hydroxide (1 ml) was left at room temperature for 20 hours then diluted with water, washed with ether and the aqueous phase separated, acidified with 2M hydrochloric acid and extracted with ether. The organic extract was dried (MgSO_4), evaporated to dryness and the residue triturated with iso-hexane to yield the title compound as a white solid. (14.0 mg, 57%).

10

^1H NMR (CDCl_3) δ : 2.08 (2H, m), 2.38, (3H, s), 2.92 (4H, m), 4.97 (2H, s), 6.85 (1H, d, $J=9\text{Hz}$), 7.00 (1H, d, $J=2\text{Hz}$), 7.14-7.22 (8H, m), 7.83 (1H, d, $J=8\text{Hz}$), 7.91 (1H, s).
 LC/MS $t=4.07$, [MH $^+$] 415.1.

15 **Example 34: 3-{2-[5-methylsulfonyl-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid**

Standard oxidation procedure**a) 3-{2-[5-methanesulfonyl-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid benzyl ester**

20

3-Chloroperbenzoic acid (53 mg, 0.236 mmol) was added to a solution of 3-{2-[5-methylsulfonyl-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid benzyl ester (51 mg, 0.1 mmol) in

dichloromethane (4 ml) and left at room temperature for 2.5 hours. The resulting solution was diluted with ether and washed with sodium thiosulphate solution and sodium bicarbonate solution then dried (MgSO_4), evaporated to dryness and the residue purified using Biotage with ethyl acetate/iso-hexane (1:4) to yield the title compound as a colourless gum. (31 mg, 58%).

5 ^1H NMR (CDCl_3) δ : 2.08 (2H, m), 2.72 (3H, s), 2.91 (4H, m), 5.04 (2H, s), 5.25 (2H, s), 6.93 (1H, d, $J=9\text{Hz}$), 7.21-7.39 (12H, m), 7.52 (1H, d, $J=2\text{Hz}$), 7.68 (1H, dd, $J=9\text{Hz}, 2\text{Hz}$), 7.74 (1H, s), 7.81 (1H, d, $J=8\text{Hz}$).

b) 3-{2-[5-methanesulfonyl-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

10

Prepared from 3-{2-[5-methanesulfonyl-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid benzyl ester using the standard hydrolysis procedure.

^1H NMR (CDCl_3) δ : 2.11 (2H, m), 2.84, (3H, s), 2.92 (4H, m), 5.09 (2H, s), 7.03 (1H, d, $J=8\text{Hz}$), 7.21-7.35 (7H, m), 7.60 (1H, d, $J=2\text{Hz}$), 7.76-7.84 (3H, m).

15 LC/MS $t=3.56$ [MH^-] 447.1.

Using the standard alkylation, hydrolysis and oxidation procedures the following compounds were prepared:

20 Example 35: 3-{2-[5-methylsulfanyl-2-(4-fluoro-benzyloxy)- phenyl]-cyclopent-1-enyl}-benzoic acid

a) 3-{2-[5-methylsulfanyl-2-(4-fluoro-benzyloxy)- phenyl]-cyclopent-1-enyl}-benzoic acid 4-fluoro-benzyl ester

25

^1H NMR (CDCl_3) δ : 2.05 (2H, m), 2.26 (3H, s), 2.85 (2H, t, $J=8\text{Hz}$), 2.93 (2H, t, $J=8\text{Hz}$), 4.85 (2H, s), 5.24 (2H, s), 6.77 (1H, d, $J=8\text{Hz}$), 6.95-7.35 (12H, m), 7.77-7.82 (2H, m).

LC/MS $t=4.42$, [MH^+] 543.1.

30 b) 3-{2-[5-methylsulfanyl-2-(4-fluoro-benzyloxy)- phenyl]-cyclopent-1-enyl}-benzoic acid

^1H NMR (CDCl_3) δ : 2.07 (2H, m), 2.30 (3H, s), 2.87 (2H, t, $J=8\text{Hz}$), 2.94 (2H, t, $J=8\text{Hz}$), 4.90 (2H, s), 6.83 (1H, d, $J=9\text{Hz}$), 6.97-7.02 (3H, m), 7.14-7.28 (5H, m), 7.83 (1H, d, $J=8\text{Hz}$), 7.89 (1H, s).

LC/MS $t=4.06$, [MH^-] 433.

35

Example 36: 3-{2-[5-methanesulfonyl-2-(4-fluoro-benzyloxy)- phenyl]-cyclopent-1-enyl}-benzoic acid

a) 3-[2-[5-methanesulfonyl-2-(4-fluoro-benzyloxy)- phenyl]-cyclopent-1-enyl]-benzoic acid 4-fluoro-benzyl ester

5 ^1H NMR (CDCl_3) δ : 2.06 (2H, m), 2.80 (3H, s), 2.85-2.94 (4H, m) 4.97 (2H, s), 5.23 (2H, s), 6.94-7.35 (8H, m), 7.57 (2H, m), 7.72-7.80 (3H, m), 7.97 (1H, d), 8.08 (1H, s).

b) 3-[2-[5-methanesulfonyl-2-(4-fluoro-benzyloxy)- phenyl]-cyclopent-1-enyl]-benzoic acid

10 ^1H NMR (CDCl_3) δ : 2.10 (2H, m), 2.87 (3H, s), 2.87-2.98 (4H, m), 5.02 (2H, s), 6.99-7.02 (3H, m), 7.16-7.28 (4H, m), 7.62 (1H, d, $J=2\text{Hz}$), 7.78-7.84 (3H, m).
LC/MS $t=3.57$, $[\text{MH}^-]$ 465.1.

Example 37: 3-[2-[5-methylsulfanyl-2-(2,4-difluoro-benzyloxy)- phenyl]-cyclopent-1-enyl]-benzoic acid

15 a) 3-[2-[5-methylsulfanyl-2-(2,4-difluoro-benzyloxy)- phenyl]-cyclopent-1-enyl]-benzoic acid benzyl ester

20 ^1H NMR (CDCl_3) δ : 2.06 (2H, m), 2.27 (3H, s), 2.84 (2H, t, $J=8\text{Hz}$), 2.91 (2H, t, $J=8\text{Hz}$), 4.95 (2H, s), 5.30 (2H, s), 6.74-6.89 (5H, m), 6.98 (1H, d, $J=2\text{Hz}$), 7.11-7.26 (4H, m), 7.37 (1H, q, $J=7\text{Hz}$), 7.76-7.79 (2H, m).

LC/MS $t=4.46$, $[\text{MH}^+]$ 579.1.

b) 3-[2-[5-methylsulfanyl-2-(2,4-difluoro-benzyloxy)- phenyl]-cyclopent-1-enyl]-benzoic acid

25 ^1H NMR (CDCl_3) δ : 2.07 (2H, m), 2.30 (3H, s), 2.86 (2H, t, $J=8\text{Hz}$), 2.94 (2H, t, $J=8\text{Hz}$), 4.95 (2H, s), 6.76-6.88 (2H, m), 7.02 (1H, d, $J=2\text{Hz}$), 7.14-7.26 (4H, m), 7.82 (1H, d, $J=8\text{Hz}$), 7.87 (1H, s).
LC/MS $t=4.09$, $[\text{MH}^-]$ 451.1.

30 Example 38: 3-[2-[5-methanesulfonyl-2-(2,4-difluoro-benzyloxy)- phenyl]-cyclopent-1-enyl]-benzoic acid

a) 3-[2-[5-methanesulfonyl-2-(2,4-difluoro-benzyloxy)- phenyl]-cyclopent-1-enyl]-benzoic acid benzyl ester


35 ^1H NMR (CDCl_3) δ : 2.07 (2H, m), 2.81 (3H, s), 2.85 (2H, t, $J=8\text{Hz}$), 2.91 (2H, t, $J=8\text{Hz}$), 5.03 (2H, s), 5.28 (2H, s), 6.80-6.90 (4H, m), 6.99 (1H, d, $J=7\text{Hz}$), 7.08-7.21 (3H, m), 7.34-7.44 (1H, m), 7.55-7.61 (1H, m), 7.75-8.10 (3H, m).

b) 3-{2-[5-methanesulfonyl-2-(2,4-difluoro-benzyloxy)- phenyl]-cyclopent-1-enyl}-benzoic acid

5 ^1H NMR (CDCl_3) δ : 2.09 (2H, m), 2.88 (3H, s), 2.85-2.96 (4H, m), 5.07 (2H, s), 6.80-6.84 (2H, m),
 LC/MS $t=3.59$, $[\text{MH}^-]$ 483.

Example 2: 3-{2-[2-Benzyl-phenyl]-cyclopent-1-enyl}-benzoic acid


10 a) 3-[2-(2-Methoxy-phenyl)-cyclopent-1-enyl]-benzoic acid ethyl ester



15 A mixture of 2-methoxyphenylboronic acid (510 mg, 3.36 mmol), 3-(2-bromo-cyclopent-1-enyl)-
 benzoic acid ethyl ester (840 mg, 2.85 mmol), potassium carbonate (3.18 g, 23.04 mmol) and
 tetrakis(triphenylphosphine)palladium(0) (370 mg, 0.32 mmol) was stirred and heated in 1:1
 toluene/ethanol (30 ml) at 90°C under nitrogen for 4 hours. After cooling the mixture was diluted
 with diethyl ether/water and the organic phase dried (MgSO_4), evaporated to dryness and the
 residue purified on Biotage using ethyl acetate/iso-hexane (1:19) to yield the title compound as a
 20 colourless gum. (615 mg, 67%).

^1H NMR (CDCl_3) δ : 1.32 (3H, t, $J=7\text{Hz}$), 2.09 (2H, m), 2.86 (2H, t, $J=8\text{Hz}$), 2.95 (2H, t, $J=8\text{Hz}$),
 3.68 (3H, s), 4.29 (2H, q, $J=7\text{Hz}$), 6.82-7.26 (6H, m), 7.76 (1H, d, $J=8\text{Hz}$), 7.84 (1H, s).

b) 3-{2-[2-(Hydroxy)-phenyl]-cyclopent-1-enyl}-benzoic acid



3-[2-(2-Methoxy-phenyl)-cyclopent-1-enyl]-benzoic acid ethyl ester (610 mg, 1.89 mmol) was dissolved in 1M boron tribromide in dichloromethane solution (18.9 ml, 18.9 mmol) and left at room temperature for 18 hours. The resulting solution was poured onto ice and extracted with dichloromethane. The organic extract was dried (MgSO_4), evaporated to dryness and purified by chromatography using biotage with iso-hexane containing a gradient of ethyl acetate (20-40%) to yield the title compound as a light brown solid. (186 mg, 35%).

¹H NMR (CDCl_3) δ : 2.14 (2H, m), 2.89 (2H, t, $J=8\text{Hz}$), 3.05 (2H, t, $J=8\text{Hz}$), 4.9 (1H, br s), 6.84 (1H, d, $J=8\text{Hz}$), 6.93 (1H, t, $J=7\text{Hz}$), 7.18-7.38 (4H, m), 7.91 (1H, d, $J=8\text{Hz}$), 7.99 (1H, s).
LC/MS $t=3.44$, $[\text{MH}^-] 279$.

Using the standard alkylation and hydrolysis procedures the following compounds were prepared.

15 c) 3-[2-(Benzylxy)-phenyl]-cyclopent-1-enyl]-benzoic acid benzyl ester

¹H NMR (CDCl_3) δ : 2.06 (2H, m), 2.90 (4H, m), 4.94 (2H, s), 5.27 (2H, s), 6.80-6.87 (2H, m), 7.00 (1H, d, $J=2\text{Hz}$), 7.13-7.36 (12H, m), 7.79 (1H, d, $J=8\text{Hz}$), 7.85 (1H, s).
LC/MS $t=4.37$, $[\text{MH}^+] 443.1$.

20

d) 3-[2-(Benzylxy)-phenyl]-cyclopent-1-enyl]-benzoic acid

¹H NMR (CDCl_3) δ : 2.08 (2H, m), 2.92 (4H, m), 5.00 (2H, s), 6.88 (1H, t, $J=8\text{Hz}$), 6.92 (1H, d, 8Hz), 7.02 (1H, dd, $J=8\text{Hz}, 2\text{Hz}$), 7.16-7.31 (8H, m), 7.81 (1H, d, $J=8\text{Hz}$), 7.91 (1H, s).
LC/MS $t=3.98$, $[\text{MH}^-] 369.1$.

Examples 39 to 41 were prepared using the standard alkylation and hydrolysis procedures.

Example 39: 3-[2-(2,4-Difluoro-benzylxy)-phenyl]-cyclopent-1-enyl]-benzoic acid

30

a) 3-{2-[2-(2,4-Difluoro-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid 2,4-difluoro-benzyl ester

5 ^1H NMR (CDCl₃) δ: 2.05 (2H, m), 2.85 (2H, t, J=8Hz), 2.91 (2H, t, J=8Hz), 4.94 (2H, s), 5.28 (2H, s), 6.74-7.37 (15H, m), 7.76 (1H, d, J=8Hz), 7.79 (1H, s).

b) 3-{2-[2-(2,4-Difluoro-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

10 ^1H NMR (CDCl₃) δ: 2.07 (2H, m), 2.87 (2H, t, J=8Hz), 2.94 (2H, t, J=8Hz), 4.99 (2H, s), 6.76-6.82 (2H, m), 6.87-6.95 (2H, m), 7.04 (1H, dd, J=8Hz, 2Hz) 7.14-7.26 (4H, m) 7.81 (1H, d, J=8Hz), 7.87 (1H, s).

LC/MS t=4.02, [MH-] 405.1.

Example 40: 3-{2-[2-(4-Chloro-2-fluoro-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

15

a) 3-{2-[2-(4-Chloro-2-fluoro-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid 4-chloro-2-fluoro-benzyl ester

20 ^1H NMR (CDCl₃) δ: 2.06 (2H, m), 2.85 (2H, t, J=8Hz), 2.92 (2H, t, J=8Hz), 4.95 (2H, s), 5.29 (2H, s), 6.86 (2H, m), 7.01-7.30 (10H, m), 7.75-7.79 (2H, m).

b) 3-{2-[2-(4-Chloro-2-fluoro-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

25 ^1H NMR (CDCl₃) δ: 2.08 (2H, m), 2.87 (2H, t, J=8Hz), 2.95 (2H, t, J=8Hz), 4.99 (2H, s), 6.88-6.92 (2H, m), 7.04-7.07 (3H, m), 7.14-7.26 (4H, m) 7.81 (1H, d, J=8Hz), 7.86 (1H, s).

LC/MS t=4.21, [MH-] 421.0, 422.9.

Example 41: 3-{2-[2-(4-Methoxy-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

30 a) 3-{2-[2-(4-Methoxy-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid 4-methoxy-benzyl ester

^1H NMR (CDCl₃) δ: 2.04 (2H, m), 2.88 (4H, m) 3.78 (3H, s), 3.82 (3H, s), 4.87 (2H, s), 5.20 (2H, s), 6.79-6.98 (7H, m), 7.11-7.32 (7H, m), 7.77 (1H, d, J= 8Hz), 7.83 (1H, s).

35 b) 3-{2-[2-(4-Methoxy-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

^1H NMR (CDCl₃) δ: 2.06 (2H, m), 2.91 (4H, m), 3.79 (3H, s), 4.92 (2H, s), 6.82-6.87 (2H, m), 6.93 (1H, d, J=8Hz), 7.01 (1H, dd, J=8Hz, 2Hz) 7.13-7.26 (6H, m), 7.81 (1H, d, J=8Hz), 7.89 (1H, s).

LC/MS $t=3.94$, [MH-] 399.1.

Example 42: 3-{2-[5-cyano-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

5 **a) 5-Cyano-2-methoxyphenylboronic acid**

This compound was prepared in a similar manner to that described for 2-methoxy-5-methylthio phenylboronic acid.

^1H NMR (DMSO-d₆) δ : 3.85 (3H, s), 7.13 (1H, d, $J=9\text{Hz}$), 7.78 (1H, d, $J=2\text{Hz}$), 7.84 (1H, dd,

10 $J=8\text{Hz}$, 2Hz) 8.03 (2H, br s).

LC/MS $t=2.13$, [MH+] 178.

b) 3-{2-[5-Cyano-2-(methoxy)-phenyl]-cyclopent-1-enyl}-benzoic acid ethyl ester

15 This compound was prepared in a similar manner to that described for 3-{2-[5-methylsulfonyl-2-(methoxy)-phenyl]-cyclopent-1-enyl}-benzoic acid ethyl ester.

^1H NMR (CDCl₃) δ : 1.34 (3H, t, $J=7\text{Hz}$), 2.10 (2H, m), 2.82 (2H, t, $J=7\text{Hz}$), 2.96 (2H, t, $J=7\text{Hz}$), 3.72 (3H, s), 4.31, (2H, q, $J=7\text{Hz}$), 6.90 (1H, d, $J=9\text{Hz}$), 7.17-7.28 (3H, m) 7.53 (1H, d, $J=9\text{Hz}$), 7.77 (1H, s), 7.81 (1H, d, $J=7\text{Hz}$).

20

c) 3-{2-[5-Cyano-2-(hydroxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

This compound was prepared in a similar manner to that described for 3-[2-(2-hydroxy-phenyl)-cyclopent-1-enyl]-benzoic acid.

25 ^1H NMR (CDCl₃) δ : 2.17 (2H, m), 2.88 (2H, t, $J=8\text{Hz}$), 3.06 (2H, t, $J=8\text{Hz}$), 5.6 (1H, br s), 6.89 (1H, d, $J=8\text{Hz}$), 7.28-7.36 (2H, m), 7.48 (1H, dd, $J=8\text{Hz}$, 2Hz), 7.53 (1H, d, $J=2\text{Hz}$), 7.94 (2H, m).

LC/MS $t=3.36$, [MH-] 304.1

d) 3-{2-[5-cyano-2-(benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

30

Prepared using the standard alkylation and hydrolysis procedures.

^1H NMR (CDCl₃) δ : 2.08 (2H, m), 2.86 (2H, t, $J=8\text{Hz}$), 2.93 (2H, t, $J=8\text{Hz}$), 5.03 (2H, s), 5.6 (1H, br s) 6.9 (1H, d, $J=8\text{Hz}$), 7.15-7.5 (9H, m), 7.8-8.0 (2H, m).

35 LC/MS $t=3.81$, [MH-] 394.1

Example 43: 3-{2-[5-cyano-2-(2,4-difluoro-benzyloxy)-phenyl]-cyclopent-1-enyl}-benzoic acid

Prepared using the standard alkylation and hydrolysis procedure.

¹H NMR (CDCl₃) δ:2.08 (2H, m), 2.83 (2H, t, 8Hz), 2.94 (2H, t, J=8Hz), 5.02 (2H,s), 5.8 (1H, br s)
6.82-6.84 (2H, m), 6.97 (1H, d, J=8Hz), 7.1-7.5 (4H, m), 7.79 (1H, s), 7.86(1H, m).

5 LC/MS t=3.84,[MH-] 430.1.

It is to be understood that the present invention covers all combinations of particular and preferred subgroups described herein above.

ASSAYS FOR DETERMINING BIOLOGICAL ACTIVITY

The compounds of formula (I) can be tested using the following assays to demonstrate their prostanoid antagonist or agonist activity *in vitro* and *in vivo* and their selectivity. The prostaglandin receptors investigated are DP, EP₁, EP₂, EP₃, EP₄, FP, IP and TP.

5 The ability of compounds to antagonise EP₁ & EP₃ receptors may be demonstrated using a functional calcium mobilisation assay. Briefly, the antagonist properties of compounds are assessed by their ability to inhibit the mobilisation of intracellular calcium ($[Ca^{2+}]_i$) in response to activation of EP₁ or EP₃ receptors by the natural agonist hormone prostaglandin E₂ (PGE₂). Increasing concentrations of antagonist reduce the amount of calcium that a given concentration of PGE₂ can mobilise. The net effect is to displace the PGE₂ concentration-effect curve to higher concentrations of PGE₂. The amount of calcium produced is assessed using a calcium-sensitive fluorescent dye such as Fluo-3, AM and a suitable instrument such as a Fluorimetric Imaging Plate Reader (FLIPR). Increasing amounts of $[Ca^{2+}]_i$ produced by receptor activation increase the amount of fluorescence produced by the dye and give rise to an increasing signal. The signal may be detected using the 10 FLIPR instrument and the data generated may be analysed with suitable curve-fitting software.

15 The human EP₁ or EP₃ calcium mobilisation assay (hereafter referred to as 'the calcium assay') utilises Chinese hamster ovary-K1 (CHO-K1) cells into which a stable vector containing either EP₁ or EP₃ cDNA has previously been transfected. Cells are cultured in suitable flasks containing culture medium such as DMEM/F12 supplemented with 10% v/v foetal calf serum, 20 2mM L-glutamine, 0.25mg/ml genetecine and 10 μ g/ml puromycin.

25 For assay, cells are harvested using a proprietary reagent that dislodges cells such as Versene. Cells are re-suspended in a suitable quantity of fresh culture media for introduction into a 384-well plate. Following incubation for 24 hours at 37°C the culture media is replaced with a medium containing fluo-3 and the detergent pluronic acid, and a further incubation takes place. Concentrations of compounds are then added to the plate in order to construct concentration-effect curves. This may be performed on the FLIPR in order to assess the agonist properties of the compounds. Concentrations of PGE₂ are then added to the plate in order to assess the antagonist properties of the compounds.

30 The data so generated may be analysed by means of a computerised curve-fitting routine. The concentration of compound that elicits a half-maximal inhibition of the calcium mobilisation induced by PGE₂ (pIC₅₀) may then be estimated.

35 By application of this technique, compounds of the examples had an antagonist pIC₅₀ value of about 7.6 at EP₁ receptors and pIC50 value of < 6.0 at EP₃ receptors.


No toxicological effects are indicated/expected when a compound (of the invention) is administered in the above mentioned dosage range.

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be

directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation the following claims:

CLAIMS

1. A compound of formula (I):



5

(I)

wherein:

A represents an optionally substituted phenyl, or an optionally substituted 5- or 6- membered heterocycl group;

10 R¹ represents CO₂R⁴, CONR⁵R⁶, CH₂CO₂R⁴, optionally substituted C₁₋₆alkyl, optionally substituted C₁₋₆alkenyl, SO₂C₁₋₆alkyl, SO₂NR⁵R⁶, NR⁵CONR⁵R⁶, tetrazolyl or CONR⁵R⁶;

R² independently represents halo, optionally substituted C₁₋₆alkyl, CN, SO₂R⁵, SOR⁵, NO₂, optionally substituted aryl, CONR⁵R⁶ or optionally substituted heteroaryl;

R^x represents optionally substituted C₁₋₈alkyl or optionally substituted -CH₂-phenyl;

15 R⁴ represents hydrogen or an optionally substituted C₁₋₆alkyl;

R⁵ represents hydrogen or an optionally substituted C₁₋₆alkyl;

R⁶ represents hydrogen or an optionally substituted C₁₋₆alkyl, optionally substituted SO₂aryl, optionally substituted SO₂heterocycl group, CN, optionally substituted CH₂aryl or COR⁷;

R⁷ represents hydrogen or an optionally substituted aryl;

20 R⁸ and R⁹ independently represent hydrogen or C₁₋₆alkyl;

n is an integer from 0 to 2;

wherein R¹ is attached to the group A in the 3 or 4 position relative to the bond attaching A to the cyclopentene ring;

or pharmaceutically acceptable derivatives thereof.

25

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.